Novartis Research and Development
JWT629 (Hydroxychloroquine)
Clinical Trial Protocol CJWT629A12301 / [STUDY_ID_REMOVED]
A multi -center, randomized, double-b linded, placebo -controlled 
study to evaluate the safety and efficacy of hy droxy chloroquine 
monotherapy and in combination w ith azithromy cin in patients w ith 
moderate and severe COVID -19 disease
Document type: Clinical Trial Protocol
EUDRACT number: Not applicable
Version number: 00 (Original Protocol)
Clinical Trial Phase: III
Release date: 08-Apr-2020 (content final)
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 3.0 (31 -Jan-2020 )
Novartis Confidential Page 2of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Table of contents
Table of contents ................................ ................................ ................................ ................. 2
List of tables ................................ ................................ ................................ ........................ 5
List of figures ................................ ................................ ................................ ...................... 6
List of abbreviations ................................ ................................ ................................ ............ 7
Glossary  of terms ................................ ................................ ................................ ................. 9
Protocol summary ................................ ................................ ................................ .............. 11
1Introduction ................................ ................................ ................................ ....................... 14
1.1 Background ................................ ................................ ................................ ............ 14
1.2 Purpose ................................ ................................ ................................ .................. 15
2Objectives and endpoints ................................ ................................ ................................ ...16
2.1 Primary  estimand ................................ ................................ ................................ ...18
2.2 Secondary  estimands ............................................................................................. 18
3Study  design ................................ ................................ ................................ ...................... 19
4Rationale ................................ ................................ ................................ ............................ 20
4.1 Rationale for stud y design ................................ ................................ ..................... 20
4.1.1 Rationale for choice of background therap y ......................................... 21
4.2 Rationale for dose/regimen and duration of treatment ................................ .......... 21
4.2.1 Rationale for h ydrox ychloroqui ne ........................................................ 21
4.2.1 Rationale for combination ................................ ................................ .....21
4.2.2 Rationale for treatment duration ................................ ........................... 22
4.2.3 Rationale for dose regimen ................................ ................................ ...22
4.3 Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ................................ ................................ ................................ ...................... 25
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..25
4.5 Risks and benefits ................................ ................................ ................................ ..25
5Study  Population ................................ ................................ ................................ ............... 26
5.1 Inclusion criteria ................................ ................................ ................................ ....26
5.2 Exclusion criteria ................................ ................................ ................................ ...26
6Treatment ................................ ................................ ................................ ........................... 28
6.1 Study  treatment ................................ ................................ ................................ ......28
6.1.1 Investigational and control drugs ................................ .......................... 28
6.1.2 Treatment arms/group ................................ ................................ ........... 28
6.1.3 Treatment duration ................................ ................................ ................ 29
6.2 Other treatment(s) ................................ ................................ ................................ ..29
6.2.1 Concomitant therap y ................................ ................................ ............. 29
6.2.2 Rescue medication ................................................................................ 29
Novartis Confidential Page 3of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
6.2.3 Prohibited medication ........................................................................... 30
6.3 Participant numbering, treatment assignment, randomization .............................. 30
6.3.1 Participant numbering ................................ ................................ ........... 30
6.3.2 Treatment assignment, randomization ................................ .................. 30
6.4 Treatment blinding ................................ ................................ ................................ .31
6.5 Additional treatment guidance ................................ ................................ ............... 31
6.5.1 Treatment compliance ................................ ................................ ........... 31
6.5.2 Emergency  breaking of assigned treatment code ................................ ..32
6.6 Preparation and dispensation ................................ ................................ ................. 32
6.6.1 Handling of study  treatment and additional treatment .......................... 32
7Informed consent procedures ................................ ................................ ............................ 33
8 Visit schedule and assessments ................................ ................................ ......................... 34
8.1 Screening ................................ ................................ ................................ ............... 36
8.1.1 Information to be collected on screening failures ................................ .36
8.2 Participant demo graphics/other baseline characteristics ................................ .......36
8.2.1 SARS -COV -2 testing ................................ ................................ ............ 36
8.2.2 Demographic information ................................ ................................ .....36
8.2.3 Prior and concomitant medications....................................................... 37
8.2.4 COVID -19 Participant status ................................ ................................ 37
8.2.5 Other baseline characteristics ................................ ................................ 37
8.3 Efficacy ................................ ................................ ................................ .................. 37
8.3.1 COVID -19 Participant status ................................ ................................ 37
8.3.2 SARS -COV -2 testing ................................ ................................ ............ 38
8.3.3 Appropriateness of efficacy  assessments ................................ .............. 38
8.4 Safety  and tolerability ................................ ................................ ............................ 39
8.4.1 Physical examination ................................ ................................ ............ 39
8.4.2 Vital signs and bod y measurements ................................ ...................... 39
8.4.3 Laboratory  evaluations ................................ ................................ .......... 39
8.4.4 Electrocardiogram (ECG) ................................ ................................ .....39
8.4.5 Pregnancy  test................................ ................................ ....................... 40
8.4.6 Appropriateness of safety  measurements ................................ .............. 40
8.5 Additional assessments................................ ................................ .......................... 41
8.5.1 Unscheduled assessments ................................ ................................ ......41
8.5.2 Assessments pre and post hospital discharge ................................ ........ 41
8.5.3 Biomarkers ................................ ................................ ............................ 41
9Study  discontinuation and completion ................................ ................................ .............. 41
Novartis Confidential Page 4of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
9.1 Discontinuation and completion................................ ................................ ............ 41
9.1.1 Study  treatment discontinuation and study discontinuat ion.................. 41
9.1.2 Withdrawal of informed consent ................................ ........................... 42
9.1.3 Lost to follow -up................................................................................... 43
9.1.4 Early study termination by the sponsor ................................ ................. 43
9.2 Study  completion and post -study  treatment ................................ .......................... 43
10Safety  monitoring and reporting ................................ ................................ ........................ 44
10.1 Definition of adverse events and reporting requirements ................................ ......44
10.1.1 Adverse event s ................................ ................................ ...................... 44
10.1.2 Serious adverse events ................................ ................................ .......... 45
10.1.3 SAE reporting........................................................................................ 46
10.1.4 Pregnancy  reporting ................................ ................................ .............. 47
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 47
10.2 Additional Safety  Monitoring ................................ ................................ ................ 48
10.2.1 Cardiac safet y monitoring ................................ ................................ .....48
10.2.2 Liver safety  monitoring ................................ ................................ ......... 48
10.2.3 Renal safet y monitoring ................................ ................................ ........ 49
10.2.4 Data Monitoring Committee ................................ ................................ .49
11Data Collection and Database management ................................ ................................ ......49
11.1 Data collection................................ ................................ ................................ .......49
11.2 Database management and quality  control ................................ ............................ 50
11.3 Site monitoring ................................ ................................ ................................ ......51
12Data analy sis and statistical methods ................................ ................................ ................ 51
12.1 Analy sis sets ................................ ................................ ................................ .......... 52
12.2 Participant demographics and other baseline characteristics ................................ .52
12.3 Treatments ................................ ................................ ................................ ............. 52
12.4 Analy sis of the primary  endpoint(s)/estimand(s) ................................ .................. 53
12.4.1 Definition of primary  estimand(s) ................................ ......................... 53
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 53
12.4.3 Handling of remaining intercurrent events of primary  estimand .......... 54
12.4.4 Handling of missing values not related to intercurrent event ............... 54
12.4.5 Sensitivity  analy ses fo r primary  endpoint/estimand ............................. 54
12.4.6 Supplementary  anal ysis................................ ................................ ......... 54
12.4.7 Supportive analy ses................................ ................................ ............... 54
12.5 Analy sis of secondary  estimands ................................ ................................ ........... 55
12.5.1 Safety  endpoints ................................ ................................ .................... 55
Novartis Confidential Page 5of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
12.5.2 Biomarkers ............................................................................................ 56
57
12.7 Interim anal yses..................................................................................................... 57
12.8
Sample size calculation.......................................................................................... 57
12.8.1 Primary  endpoint(s) ............................................................................... 57
12.8.2 Secondary  endpoint(s) ........................................................................... 58
13Ethical considerations and administrative procedures ...................................................... 58
13.1 Regulatory
 and ethical compliance ........................................................................ 58
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 58
13.3 Publication of study  protocol and results ............................................................... 59
13.4 Quality  Control and Quality  Assurance ................................................................. 59
14Protocol adherence ............................................................................................................ 59
14.1 Protocol amendments ............................................................................................. 60
15References ......................................................................................................................... 61
16Appendices ........................................................................................................................ 63
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 63
16.2 Appendix 2: Suggested Liver event and laboratory trigger definitions & 
follow -up requirements .......................................................................................... 64
16.3
Appendix 3: Suggested Specific Renal Alert Criteria and Actions and Event 
Follow -up............................................................................................................... 67
List of tables
Table 2
-1 Objectives and related endpoints .......................................................... 16
Table 4
-1 Human PK parameters from 3- compartment model describing 
human total blood hy droxy chloroquine ................................................ 24
Table 4
-2 Predicted  human exposure for 600 mg loading dose and 200 mg 
t.i.d. maintenance dose of hy droxy chloroquine sulfate ......................... 25
Table 6-1 Investigational and control drug............................................................ 28
Table 6
-2 Prohibited medication ........................................................................... 30
Table 8
-1 Assessment schedule ............................................................................. 35
Table 8
-2 Laboratory  parameters (local lab) ......................................................... 39
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ................................ ................................ ......................... 47
Table 12-1 Sensitivity  of sample size to different response rates for 148 
participants per group (N=444) and treatment differences for level 
of significance alpha = 0.05 ................................ ................................ ..57
Table 16-1 Liver event and laboratory  trigger definitions ...................................... 64

Novartis Confidential Page 6of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Table 16-2 Follow up requirement s for liver laboratory  triggers with liver 
symptoms ................................ ................................ .............................. 64
Table 16-3 Follow up requirements for liver laboratory  triggers ............................ 65
Table 16-4 Specific Renal Alert Criteria and Actions ................................ ............. 67
List of figures
Figure 3-1 Study  design ................................ ................................ .......................... 20
Figure 4 -1 Predicted concentrations of hy droxy chloroquine in the lung and 
blood compartments ................................ ................................ .............. 24
Novartis Confidential Page 7of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
List of abbreviations
AE Adverse Event
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
AST Aspartate Aminotransferase
AUC Area under the curve
AZI Azithrom ycin
BMI Body Mass Index
BUN Blood Urea Nitrogen
CL Clearance
Cmax Minimum (peak) plasma drug concentration
Cmin Maximum plasma drug concentration
CMO&PS Chief Medical Office and Patient Safety
CoV(s) Coronavirus (es)
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CSR Clinical study report
DBP Diastolic Blood Pressure
DMC Data Monitoring Committee
ECG Electrocardiogram
F Bioavailability (systemic availability of the administered dose)
FAS Full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT Gamma -glutam yl transferase
GLDH Glutamate dehy drogenase
h Hour
HCQ Hydroxychloroquine
HCT Hematocrit
Hgb Hemoglobin
HSS Department of Health and Human Services
ICF Informed Consent Form
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IN Investigator Notification
IND Investigational new drug application
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology

Novartis Confidential Page 8of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
K Potassium
ka Absorption rate constant (first order)
KG Kilogram
LFT Liver function test 
LLOQ lower limit of quantification
MedDRA Medical dictionary for regulatory activities 
Med hx Medical histor y
MERS -CoV Middle Eastern respirator y syndrome coronavirus
mg milligram (s)
Mg Magnesium
mL milliliter(s)
msec Millisecond(s)
Na Sodium
ng nanogram
o.d. Once a day
PCR Polymerase chain reaction
PLT Platelets
p.o. oral(ly)
PK Pharmacokinetic(s)
QMS Quality Management System
QTcF QT interval corrected by Fridericia’s formula
RBC red blood cell(s)
RNA Ribonucleic acid
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SARS -CoV severe acute respiratory syndrome coronavirus
sCR serum creatinine
SD standard deviation
SMQ Standardized MedDRA Query
SoC Standard of care
SpO2 Peripheral capillar y oxygen saturation
SUSAR Suspected Unexpected Serious Adverse Reaction
t.i.d. Three times a day (ter in die)
µg Microgram
ULOQ Upper limit of quantification
ULN upper limit of normal
µM Micro Molar Unit
USPI United States package insert
WBC white blood cell(s)
WHO World Health Organization 
WoC Withdrawal of Consent
Novartis Confidential Page 9of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Glossary  of terms
Additional 
treatmentMedicinal products that may be used during the clinical trial as described in 
the protocol, but not as an investigational medicinal product (e.g. any 
background therapy )
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), saliva, 
tissue, urine, stool, etc. taken from a study participant 
Control drug A study drug (active or placebo) used as a comparator to reduce assessment 
bias, preserve blinding of investigational drug, assess internal study validity, 
and/or evaluate comparative effects of the investigational drug
Dosage Dose of the study treatment given to the participant in a tim e unit (e.g. 100 mg 
once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response s ystems and clinical laboratory interfaces. EDC 
includes the use of Electronic Case Report Forms (eCRFs) which are used to 
capture data transcribed from paper source forms used at the point of care
End of the clinical 
trialThe end of the clinical trial is defined as the last visit of the last participant or 
at a later point in time as defined by the protocol 
Enrollment Point/time of participant entry into the study at which informed consent must 
be obtained 
Estimand A precise description of the treatment effect reflecting the clinical question 
posed by the trial objective. It summarizes at a population -level what the 
outcomes would be in the same patients under different treatment conditions 
being compared. Attributes of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the 
remaining intercurrent events are addressed and a population -level summary  
for the variable.
Intercurrent events Events occurrin g after treatment initiation that affect either the interpretation or 
the existence of the measurements associated with the clinical question of 
interest.
Investigational 
drug/ treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Mis-randomized 
participantsMis-randomized participants are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the stu dy 
Other treatment Treatment that may be needed/allowed during the conduct of the study (i.e. 
concomitant or rescue therapy)
Participant A trial participant (can be a healthy volunteer or a patient)
Participant number A unique number assigned to each participant upon signing the informed 
consent. This number is the definitive, unique identifier for the participant and 
should be used to identify the participant throughout the study for all data 
collected, sample labels, etc.
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and will 
be used in clinical trial database setup and eventually in analy sis
Novartis Confidential Page 10of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Personal data Participant information collected by th e Investigator that is coded and 
transferred to Novartis for the purpose of the clinical trial. This data includes 
participant identifier information, study information and biological samples.
Premature 
participant 
withdrawalPoint/time when the participant exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this time all 
study drug administration is discontinued and no further assessments are 
planned
Randomization 
numberA unique identifier assigne d to each randomized participant
Screen Failure A participant who did not meet one or more criteria that were required for 
participation in the study
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource
Start of the clinical 
trialThe start of the clinical trial is defined as the signature of the informed consent 
by the first particip ant
Study treatment Anydrug or combination of drugs or intervention administered to the study 
participants as part of the required study procedures; includes investigational 
drug(s), control(s) or background therapy
Study treatment 
discontinuationWhen the participant permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any reason; may or 
may not also be the point/time of study discontinuation 
Treatment 
arm/group A treatment arm/group defi nes the dose and regimen or the combination, and 
may consist of 1 or more cohorts.
Treatment of 
interestThe treatment of interest and, as appropriate, the alternative treatment to 
which comparison will be made. These might be individual interventions, 
combinations of interventions administered concurrently, e.g. as add- on to 
standard of care, or might consist of an overall regimen involving a complex 
sequence of interventions. This is the treatment of interest used in describing 
the related clinical quest ion of interest, which might or might not be the same 
as the study treatment.
Variable (or 
endpoint)The variable (or endpoint) to be obtained for each participant that is required 
to address the clinical question. The specification of the variable might include 
whether the participant experiences an intercurrent event.
Withdrawal of 
study consent 
(WoC)Withdrawal of consent from the study occurs only when a participant does not 
want to participate in the study any longer and does not allow any furth er 
collection of personal data
Novartis Confidential Page 11of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Protocol summary
Protocol number JWT629A12301
Full Title A multi-center, randomized, double- blinded, placebo- controlled study to 
evaluate the safety and efficacy of hydroxychloroquine monotherapy and in 
combination with azithrom ycin in patients with moderate and severe COVID -
19 disease
Brief title Hydroxychloroquine monotherapy and in combination with azithrom ycin in 
patients with moderate and severe COVID -19 disease
Sponsor and 
Clinical PhaseNovartis
III
Investigation type Drug
Study type Interventional
Purpose and 
rationaleRecently, there has been  excitement to repurpose chloroquine and 
hydroxychloroquine (HCQ) for the treatment of the patients with COVID -19, 
therefore there is an urgent need to condu ct prospective, randomized, 
double -blind, controlled clinical trials to definitively establish the benefit of 
hydroxychloroquine and the combination of hydrox ychloroquine with 
azithrom ycin in patients with COVID -19 disease.
This clinical trial is designed to evaluate the efficacy  and safety of HCQ and 
HCQ in combination with azithrom ycin compared to a placebo in adult 
participants hospitalized with moderate to severe COVID -19 disease , 
excluding critically ill participants (i.e. those needing ICU admission or 
mechanical ventilation at study start) .
Primary 
Objective(s)The primary  objective of this study is to demonstrate superiority of 
hydroxychloroquine or hydroxy chloroquine plus azithromy cin compared to 
placebo in achieving clinical response by Day 15 .
The primary  clinical question of interest is: W hat is the effect of the 
hydroxychloroquine and hydroxy choroquine plus azithromy cin versus 
placebo on the percentage of participants achieving clinical response by Day 
15 in participants with moderate to sever e COVID -19 disease excluding 
critically ill participants ( i.e. those needing ICU admission or mechanical 
ventilation at study start) who are receiving standard of care?
Secondary 
ObjectivesThe secondary objectives are:
To demonstrate superiority of hydroxychloroquine or hydroxychloroquine plus 
azithrom ycin  compared to placebo in achieving viral clearance by Day 15by 
assessing SARS -COV -2 PCR qualitative testing by day 15
To evaluate the time to discharge from the hospital in participants receiving 
hydroxychloroquine or hydroxy chloroquine plus azithromy cin relative to 
placebo by assessing time to discharge (or ready for discharge) 
To evaluate the time to return to pre -morbid supplemental oxygen 
requirement in participants receiving hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin relative to placebo by assessing the 
time to return to pre -morbid supplemental ox ygen requirements 
To evaluate the time to SARS -COV-2 negativity in participants receiving 
hydroxychloroquine or hydroxy chloroquine plus azithromy cin relative to 
placebo by assessing the time to SARS -COV -2 negativity
Novartis Confidential Page 12of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
To assess safety  of participants receiving hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin as compared to placebo by assessing 
the number of participants with adverse events, serious adverse events, 
clinically significant changes in laboratory measures, ECG and vital signs 
The clinical question of interest is: What is the effect of the 
hydroxychloroquine and hydroxy chloroquine plus azithromy cin versus 
placebo on the presence or absence of virus which will be represented by the 
percentage of participants achieving viral clearance by Day 15 in participants 
with moderate to severe COVI D-19 disease excluding critically ill participants 
(i.e. those needing ICU admission or mechanical ventilation at study start) 
who are receiving standard of care?
Study designThis study is a multi -center, randomized, blinded, three -arm parallel -group, 
placebo -controlled trial to evaluate the safety and efficacy of 
hydroxychloroquine monotherapy or in combination with azithrom ycin in 
participants with moderate and severe COVID -19 disease excluding critically 
ill participants (i.e. those needing ICU admis sion or mechanical ventilation at 
study start) .
The study will include: Screening period of up to four days to obtain the 
informed consent and assess participant ’s eligibility; Treatment period of 10 
days; and an observation period of an additional 30 days (until Day 40) with 
Day 40 being the end of study visit.
Study population The study population will consist of approximately 444 male and female adult 
participants with moderate to severe COVID -19 disease excluding critically ill 
participants ( i.e. those needing ICU admission or mechanical ventilation at 
study start) receiving standard of care to be randomized into 
hydroxychloroquine, hydroxychloroquine plus azithromycin, or placebo in 
1:1:1 ratio (148 participants / arm).
Key Inclusion 
criteriaInformed consent must be obtained prior to participation in the study
Adult patient ≥ 18 y ears old
Severe Acute Respirator y Syndrome Coronavirus (SARS -CoV) -2 
infection confirmed by polymerase chain reaction (PCR) test or rapid test 
from respiratory tract specimen ( e.g.nasopharyngeal swab) within 4 day s 
prior to randomization
Currently hospitalized or requiring hospitalization due to COVID -19 
disease
Key Exclusion 
criteriaUse of other investigational drugs within 5 half -lives or 30 days of 
enrollment
Participatio n in any other clinical trial of an experimental treatment for 
COVID -19 within 5 half -lives or 30 days of enrollment 
Expectation of concurrent treatment with other agents with actual or 
potential direct acting antiviral activity against SARS -CoV-2
History of hypersensitivity to any of the study treatments or its excipients 
or to drugs of similar chemical classes.
Requires, in the judgement of the investigator, admission to the intensive 
care unit (ICU) or mechanical ventilator y support (invasive or non -
invasive) prior to the initiation of study drug
Evidence of cytokine storm syndrome or multi -organ s ystem failure or 
confirmed co -infection with influenza
History or current diagnosis of ECG abnormalities
Novartis Confidential Page 13of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Pregnant or lactating women
Study treatment Hydroxychloroquine and matching placebo, azithrom ycin and matching 
placebo
Treatment of 
interestThe study treatment consists of:
Investigational drug
Hydroxychloroquine (HCQ): doses of 200 mg or placebo
Azithrom ycin (AZI): dose of 250 mg or placebo
All participants will receive best standard of care as background therapy. 
Further details about the investigational treatment and control treatment are 
provided in Section 6 .
Efficacy 
assessmentsCOVID -19 participant status  
 
), SARS -COV -2 testing
Key safety 
assessmentsAdverse event monitoring, Phy sical examinations, vital signs, monitoring of 
laborator y markers in blood and urine etc. ECGs
Other 
assessments 
Data analysis The primary  efficacy  endpoint (percentage of participants with clinical 
response by Day 15) is defined:
for participants with a pre-morbid oxygen requirement :as discharge (or 
ready to discharge as evidenced by normal body temperature and 
respirator y rate, and stable oxygen saturation on ambient air or ≤ 2L 
supplemental ox ygen) OR survival without need for mechanical 
ventilation
for participants without a pre -morbid oxygen requirement : as discharge 
(or ready for discharge) OR survival without need for mechanical 
ventilation or oxygen supplementation for the last 24 hours.
The primary  analy siswill use a logistic regression model . 
The secondary endp ointcontrolled for multiplicity ,will be the percentage of 
participants with viral clearance (SARS -CoV-2 negativity) by day 15.This 
endpoint will be analyzed using a logistic regression model . 
Key words COVID -19, corona virus, SARS -CoV

Novartis Confidential Page 14of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
1 Introduction
1.1 Background
Coronavirus (CoVs) are positive -sense single stranded enveloped RNA viruses, many of which 
are commonly  found in humans and cause mild symptoms. Over the past twodecades, emerging 
pathogenic CoVs capable of causing life-threatening disease in humans and animals have been 
identified, namel y severe acute respiratory  syndrome coronavirus (SARS -CoV) and Middle 
Eastern respiratory  syndrome coronavirus (MERS -CoV).
In December 2019, the Wuhan Municipal Health Committee (Wuh an, China) identified an 
outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified 
in some of these patients. This novel coronavirus has been abbreviated as SARS -CoV-2 and 
has 89% nucleotide identity  with bat SARS -like-CoVZ XC21 and 82% with that of human 
SARS -CoV -1. Initially , most of the infections outside China were travel -associated cases in 
those who had recentl y visited the city of Wuhan ,and thought to have acquired the virus through 
contact with infected animals or contact with infected people. However, in recent weeks, the 
world has seen an increasing number of cases (> 800,000 confirmed cases worldwide and > 
180,000 confirmed cases in the US by 31stMarch 2020), primaril y the result of community  
transmission accordin g to World Health Organization ( WHO 2020). 
Thenovel coronavirus has been designated SARS -CoV -2, and the disease caused by ithas been 
designated COVID -19,which leadsto substantial morbidity  and mortality . Outbreak 
forecasting and mathematical modeling suggest sthat these numbers will continue to rise
(Ferguson et a l 2020 ). Global efforts to evaluate novel antivirals and therapeutic strategies to 
treat COVID- 19 have i ntensified. There are currently  no vaccine or ther apies to prevent or treat 
SARS -CoV -2 infection. Therefore, there is an urgent public health need for rapid research and 
development of novel therapeutics.
Recently , there has been excitement to repurpose c hloroquine and hy droxychloroquine (HCQ) 
for the treatment of the patients with COVID -19; these are products that were originall y 
approved for malaria in 1949 and 1955, respectively.  Both products have well-established 
safet y profiles ,with marketed use ov er 60 yearsfor treatment of malaria, rheumatoid arthritis, 
and systemic lupus ery thematosus. Both have anti-viral as well as immunomodulatory  effects, 
including effects on innate immune pathway s and downstream cytokines like IL-6 (van d en 
Borne e t al 1997 ).Further, there are several publications out of China on the use of c hloroquine ,
and t here are 16 clinical studies ongoing with chloroquine according to the clinical trial registry 
in China ( accessed on March 22nd, 2020).
HCQ is reported to have a more favorable safet y profile ,with less toxicity  and drug interactions 
compared to chloroquine. In addition, arecent publication hasreported that compared to 
chloroquine, HCQ also hasgreater potency in vitro against SARS -CoV -2 (Liu et al 2020 ).
However, hydroxychloroquine has potential short and long-term toxicities, and definitive 
benefit needs to be established to outweigh the known potential risks .
Data from a small open label study  in France using HCQ , with or without addition of 
azithromy cin, was recently reported (Gautret et al 2020 ). In this study  26 patients with COVI D-
19 were treated with 600 mg daily  of HCQ ( 200 mg t.i.d.) for 10 day s (with 6 of these patients 
also receiving azithromycin) . The endpoint was virologic clearance from nasopharyngeal swabs 
Novartis Confidential Page 15of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
at Day 6. External controls included patients at another center ,or patients at the same center 
who decli ned participation ,or had an exclusion criteria. Six of the 26 patients were lost to 
follow -up (3 to ICU; 1 death; 1 left the hospital; 1 stopped treatment due to nausea).  Of the 
remaining 20 who completed, 70% of patients with HCQ were virologically  cured compared 
with only 12.5% of the sixteen control s ubjects. Further, a recent re-analysis of the data suggest s
a potential benefit of the combination ( Lover 2020 ).
In addition, asmall blinded, randomized, controll ed study  from Wuhan in patients with 
COVID -19 pneumonia (31 patients in the treatment group and 31 in the control group), reported 
after five days of treatment with hydroxychloroquine, significant improvements in the treatment 
group in fever, cough, and in pneumonia ( Chen et al 2020 ).There is an urgent need to conduct 
prospective , randomized, double -blind , controlled clinical trials to definitive lyestablish the 
benefit of hy droxychloroquine and the combination of h ydrox ychloroquine with azithromy cin 
in patients with COVI D-19 disease .
1.2 Purpose
This clinical trial is designed to evaluate the efficacy  and safet y of HCQ and HCQ in 
combination with azithromycin compared to a placebo in adult participants hospitalized with
moderate to severe COVID -19 disease .
Patients with m oderate COVID -19 disease are considered to be those with peripheral capillary 
oxygen saturation (SpO2) > 94% on room air and requiring hospitalization; patients with severe 
COVID -19 disease are those requir inghospitalization with peripheral capillary  oxygen 
saturation (SpO2) ≤ 94% on room air, or the need for oxygen supplementation; respiratory  
rate >24 breaths per min; heart rate >100 beats per min; systolic blood pressure <90 mm Hg). 
However, in this study , participants critically  ill who requir emechanical ventilation or 
admission to an intensive care unit prior to the initiation of study  treatment are excluded.
This study  is being conducted to determine whether oral hydroxy chloroquine can safel y and 
effectivel y be used to mitigate, treat, or cure COVID -19 or limit the harm of the COVID -19 
pandemic in accordance with the Secretary  of the Department of Health and Human Services’ 
(HHS’s) Declaration under the Public Readiness and Emergency Preparednes s Act for medical 
countermeasures against COVID -19 (COVID -19 Declaration) effective February  4, 2020. In 
addition, the purpose of this study  is to test whether oral hydroxy cholorquine drug product, 
either as a monotherap y or in combination with azithromy cin, results in clinical benefit in 
patients hospitalized with COVID -19. This study  is authorized to proceed under an approved 
investigational new drug application (IND) in accordance with the public health and medical 
response of FDA, an Authority  Having Jurisdiction as described under the PREP Act, to 
prescribe, administer, deliver, distribute or dispense this Covered Countermeasure as defined 
by and following the HHS’s COVID -19 Declaration.
Novartis Confidential Page 16of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objectives Endpoints
Primary Objective
To demonstrate superiority of 
hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin  
compared to placebo in achieving clinical 
response by Day 15Endpo intsfor primary objective
The percentage of participants who achieve clinical 
response by Day 15 defined as: 
For participants with a pre -morbid oxygen 
requirement:
Discharge (or ready for discharge as 
evidenced by normal body temperature and 
respirator y rate, and stable oxygen 
saturation on ambient air or ≤2L 
supplemental ox ygen ) OR
Survival without need for mechanical 
ventilation
For participants without a pre -morbid oxygen 
requirement:
Discharge (or ready for discharge) ; OR
Survival without need for mechanical 
ventilation or oxygen supplementation for 
the last 24 hours
Secondary Objectives Endpoints for secondary objectives
To demonstrate superiority of 
hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin  
compared to placebo in achieving viral 
clearance by Day 15The percentage of participants with negative or 
below LL OQ SARS -COV -2 based on 
polymerase chain reaction (PCR) test by Day
15
To evaluate the time to discharge from 
the hospital in participants receiving 
hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin
relative to pla ceboTime to discharge (or ready for discharge)   
To evaluate the time to return to pre-
morbid supplemental oxygen 
requirement in participants receiving 
hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin 
relative to placeboFor the subset of patients who require supplemental 
oxygen atthe time of randomization:
Time to return to pre-morbid supplemental 
oxygen requirement
To evaluate the time to SARS -CoV-2 
negativity in participants receiving 
hydroxychloroquine or 
hydroxychloroquine plus azithrom ycin 
relative to placeboTime to SARS- CoV-2 negativity
To assess safety  of participants 
receiving hydroxychloroquin eor 
hydroxychloroquine plus azithrom ycin as 
compared to placeboNumber of pa rticipan ts with adverse events
(AE), serious adverse events (SAE), clinically 
significant changes in laboratory measures, 
ECG and vital signs 
Novartis Confidential Page 17of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Objectives Endpoints
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 

Novartis Confidential Page 18of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Objectives Endpoints
  
 
 
 
2.1 Primary  estimand
The primary  clinical question of interest is: What is the effect of the hydroxy chloroquine and 
hydroxychoroquine plus azithromy cin versus placebo on the percentage of participants
achieving clinical response byDay 15 in participants with moderate to severe COVID -19 
disease who are receiving standard of care ?
The justification for the primary  estimand is that it will capture both the effect of the study 
treatments and the effect of any standard of care treatments, dosed as required that they are 
receiving at the time of randomization, mirroring the conditions in clinical practice. Further 
details can be found in Section 12.
The primary  estimand is described by  the following attributes:
Population: Adults at least 18 years of age, with SARS -COV -2 confirmed by P CR or rapid test 
≤
4 days prior torandomization who are currently hospitalized or who require hospitalization
for COVID -19 disease . Further details about the population are provided in Section 5.
Endpoint: Clinical response by Day 15 defined for participants with a pre-morbid oxygen 
requirement as: Discharge (or ready for discharge as evidenced by normal body  temperature 
and respiratory  rate, and stable oxygen saturation on ambient air or ≤2L supplemental oxygen) 
OR survival without need for mechanical ventilation.
Clinical response b y Da y 15 defined for participants without a pre -morbid oxy gen requirement 
as: Discharge (or ready for discharge) OR survival without need for mechanical ventilation or 
oxygen supplementation for the last 24 hours.
Treatment of interest: The randomized treatment (hydroxychloroquine orhydroxy chloroquine
plus azithromy cin or placebo ) added to concomitant standard of care treatments used to treat 
moderate -severe COVID -19 disease . Further details about the investigational treatment and 
control treatment are provided in Section 6.
Based on the definition of the endpoint there are no intercurrent events which need to be 
accounted for outside of the treatment of interest attribute of the estimand . 
The summary  measure: Odds -
ratio comparing experimental treatments of interest to placebo
2.2 Secondary  estimands
The clinical question of interest is: What is the effect of the hydroxy chloroquine and 
hydroxychloroquine plus azithromy cin versus placebo on the presence or absence of virus 
which will be represented by the percentage of participants achieving viral clear ance byDay 15
in participant s with moderate to severe COVID -19 disease who are receiving standard of care?

Novartis Confidential Page 19of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
The justification for the secondary estimand is that it will capture both the effect of the study 
treatments and the effect of any standard of care treatments, dosed as required at the time of 
randomization, mirroring the conditions in clinical practice. Further details can be found in 
Section 12.
The secondary estimand is described by  the following attributes:
Population: Adults at least 18 years of age, with SARS -COV -2 confirmed by PCR or rapid test 
≤4 days prior to randomization who arecurrentl y hospitalized or who require hospitalization 
for COVID -19 disease. Further details about the population are provided in Section 5 .
Endpoint: The percentage of participants with negative or below LL OQ -SARS- COV -2 based 
on PCR byDay 15
Treatment of interest: the randomized treatment (hydroxy chloroquine orhydroxychloroquine
plus azithromy cin or placebo ) added to concomitant standard of care, used to treat moderate -
severe COVID -19 disease . Further details about the investigational treatment and control 
treatment are provided in Section 6 .
Handling of remaining intercurrent events will be considered as treatment failures (Composite 
strategy ):
Death
The summary  measure: Odds -ratio comparing experimental treatments of interest to placebo
3 Study  design
This study  is a mu lti-center, randomized, blinded, three -arm parallel -group , placebo -controlled 
trial to evaluate the safety  and efficacy  of hy droxy chloro quine monotherapy  or in combination 
with azithromy cin in participants with moderate and severe COVID -19 disease.
The study  will include: Screening period of up to four daysto obtain the informed consent and 
assess participant ’s eligibility; Treatment period of 10 days; and an observation period of an 
additional 30 day s (until Day 40)with Day  40 being the end of study  visit .All p articipants are 
expected to be treated with available standard of care (SoC)therap y for COVID -19 disease 
throughout the study . Approximately  444 participants will be randomized into either of three 
arms with 1:1:1 ratio . The clinical visit schedule and the details of procedures to be performed 
at each visit are listed in Table 8-1.
Novartis Confidential Page 20of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Figure 3-1 Study  design
All participants will be treated with the best available standard of care for COVID- 19 disease throughout the study
1The total treatment duration of hydroxychloroquine will be 10 days .The total treatment duration of azithromycin will be 
5 days. In case a participant is discharged before the end of treatment period (Day 10) he/she may continue study 
medication at home until Day 10 if QTcF ≤ 480 ms at the time of discharge based on the local ECG data . Otherwise, 
treatment will be discontinued at the time of discharge (before Day 10) .
2 The loading dose of AZI/matching placebo (Day 1) should be taken 4 hours after loading dose of HCQ/matching 
placebo
3After HCQ/matching placebo loading dose on Day 1, the following HCQ/matching placebo dose sas a maintenance 
therapy should be initiated within approximately 8 hours (not to exceed 12 hours ).
HCQ: hydroxychloroquine, AZI: azithromycin, o.d.: once a day , t.i.d: three times a day
4 Rationale
4.1 Rationale for study  design
The study  is designed as a prospective randomized, double blind , placebo -controlled trial in 
order to reduce the likelihood of imbalances in the study  population, and bias in the evaluati on
of clinical response. The three-arm parallel design allows contemporaneous evaluations of three 
treatment regimens, and mitigates confounders related to the rapidl y changing landscape of 
therapies and outcomes ac ross various healthcare sy stems.
Inclusion of hospitalized patients allows for careful assessment of clinical response and 
monitoring of safet y. The study  includes a population who is moderatel y to severel y ill, and at 
risk for developing complications of COVID -19 disease, in order to demonstrate the potential 
benefit in the clinical response and impact on the progression of disease. The study  excludes 
patients who are critically  ill at screening to reduce efficacy  and safety  confounders and as there 
is no evidence at this stage to assume the study  treatment would be beneficial at this stage of 
the disease.

Novartis Confidential Page 21of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
4.1.1 Rationale for choice of background therapy
All participants will receive best standard of care as background therap y. Although there are no 
specific therapies approved for thetreatment of COVID -19, participants with moderate and 
severe disease are expected to receive supportive care as dictated b y local treatment guidelines. 
Depending on the disease severity , supportive care may include the use of oxygen 
supplementation, antibiotic proph ylaxis, and other concomitant medications for comorbidities, 
ventilator support ,and intensive care management in the event of disease progression.
4.2 Rationale for dose/regimen and duration of treatment
4.2.1 Rationale for hy droxychloroquine
Hydroxy chloroquine is a medication approved by the US Food and Drug Administration for a 
variet y of indications, including treatment of malaria, rheumatoid arthritis, and systemic lupus
erythematosus (Schrezenmeier and Dorner 2020 ). Hydroxychloroquine and chloroquine are 
alkalinizing lysosomatropic drugs that accumulate in lysosomes (Vincent et al 2005 and 
Ponticelli and Moroni 2017 )and block viral infection by increasing endosomal pH, which is 
required for viral participles to fuse with a cell. The effect of hydroxychloroquine on the 
replication of SARS -CoV -2 and similar coronaviruses has been recently described in the 
laboratory  (Yao et al 2020 ). In addition to its antiviral properties, hydroxychloroquine treatment 
may inhibit several pathway s relevant to COVID -19 pathology , including inhibition of viral 
nucleic acid-mediated activation of various innate immu ne pathway s (Toll -like receptors 7, 8 
and 9) (Schrezenmeier and Dorner 2020 ). Modulation of these pathways would result in 
inhibition of viral nucleic acid-induced cytokine production, reducing levels of interleukin (IL)-
6, IL-1b, type 1 interferons (IFNs) and tumor necrosis factor (TNF), and potentially  reducing 
the clinical sequelae of excessive immune activation, including cytokine release syndrome 
(CRS) ( Mehta et al 2020 ).Further more , hydroxy chloroquine would be expected to block other 
immune effector functions dependent on lysosomal -endosomal function, including antigen 
presentation, which in the context of excessive tissue inflammation, may also reduce tissue 
damage medi ated by T cells. Recent small clinical studies and clinical case series in COVID -
19-infected patients have suggested that hydroxychloroquine and chloroquine are superior to 
control treatments in inhibiting the exacerbation o f pneumonia, shortening the d ise ase, 
improving lung imaging findings and viral clearance. (Gao et al2020 andGautret et al2020 ). 
Taken together these data suggest that hydroxy c hloroquine may be beneficial in the treatment 
of patients with moderate to severe COVID -19 disease (Colson et al 2020 ).
4.2.1 Rationale for combination
A recent publication ( Gautret et al 2020) suggested that h ydrox ychloroquine treatment at doses 
of 600 mg dail y  (200 mg t.i.d) (with or without azithromycin) resulted in virologic clearance in 
70% of treated COVID -19 patients compared with 12.5% of controls by Day 6. The results 
were most pronoun ced in the subjects that receive azithromy cin in combination with HCQ.The 
mechanisms by which azithromy cin may have contributed to enhanced viral clearance in this 
small study  are unknown (Lover 2020 ).
Macrolide antibiotics accumulate in polymorphonuclear leukocy tes and macrophages reaching 
high intracellular c oncentrations ( Bosner e t al2005 ). A number of in vivo and in vitro studies, 
Novartis Confidential Page 22of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
as well as clinical findings, confirm macrophages as one of the target cells of macrolide 
antibiotics. Inhibitory  effects of azithromy cin on LPS-induced lung neutrophilia can be 
explained, at least partially , by inhibition of GM-CSF and IL-1β production by macrophages. 
Further, their ability  to inhibit IL-6 and PGE2 production c orrelates with macrolide 
accumulation in cells, as well as with their binding to phospholipids (Banjanac et al 2012 ). In 
clinical studies, in addition to its antibacterial propert ies, azithromy cin immunomodulatory 
effects have been proven beneficial in a variet y of inflammatory  acute and chronic lung diseases 
such as, community  acquired pneumonia, cystic f ibrosis, bronchiectasis, COPD, and others; and 
may be beneficial in patients with COVID -19 disease (Amsden 2005 ). Azithromy cin will be 
dosed in accordance to the label for a total duration of 5 day s. 
4.2.2 Rationale for treatment duration 
A short -term duration of 10 days is proposed . Modeling and simulation described in Section
4.2.3 suggest adequate concentrations in the lung for > 28 days. Clinical data suggest t hat the 
maximum anti-viral effect may be achieved the first 5-6 days of therap y (Gautret e t al 2020 ), 
while anti-inflammatory  effects may be beneficial over longer periods. W hen used for short 
periods, hydroxy chloroquine is generall y well tolerated, with the most common side effects 
including nausea, vomiting, diarrhea, rash, and headache (Ponticelli and Moroni 2017 ). Further, 
indouble -blind trials in patients with rheumatoid a rthritis, 6 w eeks of treatment with HCQ at 
400 mg/day  (n =71), 800 mg/day  (n= 71 ), and 1,200 mg/day  (n= 66), followed by  18 weeks of 
open label HCQ treatment at 400 mg/day , toxicity  was not dose related and was relativel y mild. 
In particular, 800 mg/day and 1,200 mg/day  HCQ dosages were not associated with more ocular 
toxicit y compare d with the 400 mg/day  (Furst et al 1999 ). The protocol exclusion criteria will 
be in place based on the known safety  profile of HCQ, and the sponsor will closely  monitor 
safet y. 
4.2.3 Rationale for dose regimen
The propo sed hydroxychloroquine (HCQ )regimen is 600 mg loading dose followed by 200 mg 
three times daily  for the first 10 days of the study . The total treatment duration of 
hydroxychloroquine will be a maximum of 10 days. The approach includes a loading dose on 
Day 1 to reach the target concentration in the lu ng tissue within the first 5 hours . The proposed 
regimen isexpected to enable optimal inhibition of both viral and inflammatory  pathway s by 
HCQ. Three times a daily regimen is selected to mitigate Cmax relate d to cardiac safety  risk.
Recently  published literature describes the effect of HCQ on the replication of SARS -CoV -2 
and similar coronavir uses, in vitro. F ull dose response curves of the antiviral activity  of HCQ 
in an in vitro assay  using Vero E6 kidne y epithelial cells infected with SARS -CoV -2 have been 
published (Yao et al 2020 ). Depending on the time point (24 or 48 hours post infection) the 
EC50 v alues range from 0.72 –6.25 µM and t he EC90 values from 1.5 –15 µM.  Furthermore, 
HCQ EC50 values of 8 µM have been reported in similar in vitro assay s for other human -tropic 
coronaviruses (Dyall et al 2014 ). Based on the totality  of in vitro data, weanticipate a 
significant effect of H CQ onSARS -CoV -2viral load in patients at an HCQ target 
concentrations of greater than 15 µM (5040 ng/mL) of free base in lung tissue.
The HCQ PK model was constructed based on published clinical data ( Tettet al 1988 andTett 
et al 1989 ). The combined clinical data was best described by a 3-compartment m odel with 
Novartis Confidential Page 23of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
absorption into and linear elimination from the central compartment, and distribution into 
peripheral compartments. The human PK parameters from the 3-compartment model are 
summarized in Table 4-1. The simulations took into consideration that anoral dosage form of 
200 mg hydroxychloroquine sulfate contains 155 mg hydroxychloroquine. The large volume of 
distribution indicates that HCQ is highly  bound to tissues. To simulate the concentration of 
HCQ in the lung we a ssume direct and rapid partitioning from the central compartment with a 
partition coefficient of Kp = 50.6 ( Wei et al 1995 ). 
The simulated concentration time curves for HCQ in the lung and blood for either 600 mg o.d.
HCQ sulfate (light gray , regimen),or a loading dose of 600 mg followed by 200mg t.i.d. (dark 
red) are presented in Figure 4-1.Additionally ,co-administration ofazithromy cinis not 
expected to have aneffect on HCQ concentrations (Yeates et al 1996 and Mattila et al 1994 ).
The dosing regimen of 600 mg loading dose followed by 200 mg t.i.d. hydroxychloroquine 
sulfate enables rapid attainment and maintenance of the target lung concentration of 15 µ M. 
Table 4-2 summarizes the Cmax, Cmin and AUC values for HCQ in blood.  
Novartis Confidential Page 24of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Figure 4-1 Predicted concentrations of hy droxychloroquine in the lung and blood 
compartments
Figure 4 -1:A regimen consisting of a 600 mg HCQ sulfate loading dose on Day 1 followed by 200 mg t.i.d. (red) 
is compared against a 600mg o.d.regimen (grey) . While the y -axis represents concentrations of HCQ (free base), 
doses are expressed as HCQ sulfate tablets. The horizontal line denotes a target threshold of 15 μM (5040 
ng/mL). a) Predicted PK profile for day 1 b) Predicted PK profile from day 1 to day 10  C) Predicted PK profile 
followed by a washout period to reach the threshold of EC90.
Table 4-1 Human PK parameters from 3 -compartment model describing human 
total blood hy droxychloroquine
Parameter Units Estimate 95% Confidence Interval
V1 L 193.6 [161.1,228.7]
V2 L 3519.1 [3024.6,4150.2]
CL L/h 5.67 [5.37,5.99]
Q12 L/h 2.42 [1.95,3.05]
ka 1/h 0.156 [0.125, 0.199]
F dimensionless 0.79 (fixed)
V3 L 2274.5 [2021.1,2546.1]
Q13 L/h 47.5 [40.9,54.9]

Novartis Confidential Page 25of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Table 4-2 Predicted  human exposure for 600 mg loading dose and 200 mg t.i.d. 
maintenance dose of hydroxychloroquine sulfate
Mean 95% Confidence Interval
Cmax (ng/mL)Day 1, 0 -8hr 511.8 [433.2, 600.3]
Day 1 525.2 [460.9, 600.3]
Day 10 1128.6 [1059.4, 1197.8]
Cmin (ng/mL)Day 1 382.15 [342.4, 417.8]
Day 10 1012.5 [944.4, 1087.3]
AUC (ng/mL*hr)Day 1 10603 [9484, 11696]
Day 10 25690 [24080, 27413]
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
All participants will receive best standard of care for the treatment of COVID -19 disease and 
therefore placebo is only  used to control the blind for the arms .
4.4 Purpose and timing of interim analy ses/design adaptations
No formal interim analysis is planned for this trial.  The primary  endpoint analysis will be 
performed after all participants have completed Day 15 or discontinued prior to Day 15.  A final 
analysis will be performed after all participants have completed their last follow -up visit at Day 
40 (or discontinued prior to Day  40).
4.5 Risks and benefits
Appropriate eligibility  criteria and clinical safety  monitoring criteria are included in this 
protocol. The risk to participants in this trial may be minimized by compliance with the 
eligibility  criteria and study  procedures, as well as close clinical monitoring .Refer to the
Hydroxy chloroquine USPI  (2018) /applicable labelling information .
There are currentl y no drugs approved for the treatment of patients with COVID -19, and there 
is a high medical need to control the global pandemic . Given the results of studies outlined 
above, HCQ as monotherapy or in combination with azithromy cin, along with standard of care 
(SoC) treatment ,offers a prospect of benefit inpatients with moderate to severe COVID -19 
disease more effectively  than current SoC alone. Safety data have previously  been generated on 
the use of HCQ and azit hromy cinin other indications. Therefore, a placebo -controlled study in 
combination with SoC isjustified to address the high unmet need in the target patient population.
The safet y profile of HCQ is described in the USPI / applicable labelling information and also 
re-iterated in the FDA HCQ fact sheet for health care providers Emergency  Use Authoriz ation 
(EUA) dated 3/28/2020 . Long term use has been associated with ocular toxicity and caution in 
administration to patients with hepatic/renal disease arewell known. Investigators should also 
be aware that other precautions should be taken as per label (e.g. participants with glucose -6-
phophate dehydrogenase (G-6-PD) deficiency ) and anticipate any potential drug interactions.
For azithromy cin, equal diligence should be in place for participants with impaired liver 
function (primary  elimination via liver) and impaired renal function. There are clinical safet y 
hepatic and renal monitoring guidance in place and should be easily  monitored in the hospital
Novartis Confidential Page 26of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
setting. Participants should also be closel y monitored for signs and symptoms of hypoglycemia, 
particular ly those who are diabetic and taking anti-diabetic medications. More relevant to the 
short term administration of HCQ and azithromy cin is drug-induced QT interval prolongation 
and potential pro-arrhy thmic effects . To that end, in addition to relevant cardi ac exclusion 
criteria, participants will also need to follow cardiac safety monitoring, with clear guidance on 
when to discontinue study medication swith regard to QTcF changes. In the setting of active 
COVID -19 disease in the study  population, the benefits of short -term treatment in a hospital 
setting should ,in principle outweigh the known potential risks.
Women of child- bearing potential and sexually  active males must be informed that taking the 
study  treatment may  involve unknown risks to the fet us if pregnancy  were to occur during the 
study , and agree that in order to participate in the study  they must adhere to the contraception 
requirements outlined in the exclusion criteria. If there is any  question that the participant will 
not reliably  compl y, they should not be entered or continue in the study.
5 Study  Population
The study  population will consist of approximately 444male and female adult participants with 
moderate to severe COVID -19 disease receiving standard of care to be randomized into 
hydroxychloroquine, hydroxychloroquine plus azithromy cin, or placebo in 1:1:1 ratio (148
participants / arm).
5.1 Inclusion criteria
Participants eligible for inclusion in this study  must meet allof the following criteria prior to 
randomization:
1. Informed consent must be obtained prior to participation in the stud y
2. A dult patient ≥18 years old
3.Severe Acute Respiratory S yndrome Coronavirus (SARS -CoV) -2 infection confirmed b y 
polymerase chain reaction (PCR) test or rapid test from respiratory  tract specimen (e.g .
nasophary ngeal swab) within 4 day s prior to randomization
4.Currently  hospitalized or requiring hospitalization due to COVID -19 disease
5.2 Exclusion criteria
Participants meeting an y of the following criteria are not eligible for inclusion in this study .
1.Use of o ther investigational drugs within 5 half -lives or 30 day s of enrollment whichever 
is longer
2.Participation in any  other clinical trial of an experimental treatment for COVID -19within 
5 half -lives or 30 day s of enrollment whichever is longer
3. Expectation of concurrent treatment with other agents with actual or potential direct acting 
antiviral activity  against SARS -CoV -2during study  drug dosing period, including but not 
limited to oseltamivir and protease inhibitors
4.History  of hypersensitivity  to any  of the study  treatments or its excipients or to drugs of 
similar chemical classes.
Novartis Confidential Page 27of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
5.Requires, in the judgement of the investigator, admission to the intensive care unit (ICU)
or mechanical ventilatory support (invasive or non -invasive) prior to the initiation of study 
drug
(There might be a participant who cannot beadmitted to the ICU, even if the participant’s 
condition is severe enough ,due to administrative reason sunder the current circumstance s. 
This case is also considered under admission to the ICUjudged b y the investigator)
6.Evidence of cytokine storm sy ndrome or multi -organ s ystem failure
7.Confirmed co- infection with influenza
8.Creatinine clearance < 45mL/min or requiring acute renal replacement therap y
9.History  or current diagnosis of ECG abnormalities indicating significant risk of safet y for 
participants part icipating in the study  such as:
Concomitant clinically  significant cardiac arrh ythmias, e.g. sustained ventricular 
tachycardia, and clinically significant second or third degree AV
History  of familial long QT sy ndrome or known family  history  of Torsades de Pointe
QTcF > 4 80 msec ( at screening and/or Day 1at pre -dose)based on the local ECG 
data
Uncorrected electrol yte abnormalities, such as hy pokalemia, hy pomagnesemia and 
hypocalcemia
Use of agents known to prolong the QT interval within 5 half- lives before screening
10.Any other condition (e.g. known liver disease )which, in the opinion of the investigator, 
would put the safety  of the participant at risk, impede compliance or hinder completion of 
the study
11.Pregnant or nursing (lactating) women
12.Women of child- bearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they are using basic methods of contraception during dosing of 
study  treatment. Basic contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
participant. Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post -
ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y, or tubal ligation at least six weeks before taking 
investigational drug. In case of oophorectom y alone, only when the reprod uctive 
status of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female participants on the 
study , the vasectomized male partner should be the sole partner for that participa nt
Barrier methods of contraception: Condom or Occlusive cap (e.g. diaphragm or 
cervical/vault caps).
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have compa rable efficacy  
(failure rate <1%), for example hormone vaginal ring or transdermal hormone 
Novartis Confidential Page 28of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem 
(IUS).
In case of use of oral contraception women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
Women are considered post -menopausal and not of child bearing potential if they  have had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropria te history  of vasomotor symptoms) or have had surgical bilateral oophorectom y (with 
or without hysterectomy ), total hysterectomy  or bilateral tubal ligation at least six weeks ago. 
In the case of oophorectomy  alone, only when the reproductive status of thewoman has been 
confirmed by follow up hormone level assessment is she considered not of child bearing 
potential.
If local regulations deviate from the contraception methods listed above to prevent pregnancy , 
local regulations appl y and will be described in the I CF.
6 Treatment
6.1 Stud y treatment
6.1.1 Investigational and control drugs
The study  treatment consists of:
Investigational drug
Hydroxychloroquine (HCQ) : doses of 200 mg or placebo
Azithromy cin (AZI): dose of 250 mg or placebo
Table 6-1 Investigational and control drug
Investigational/ 
Control DrugPharmaceutical 
Dosage FormRoute of 
AdministrationSupply Type Sponsor (global 
or local)
HCQ 200 mg Tablet Oral use Open label Sponsor global
HCQ Placebo Tablet Oral use Open label Sponsor global
AZI 250 mg Tablet Oral use Open label Sponsor global
AZI Placebo Tablet Oral use Open label Sponsor global
6.1.2 Treatment arms/group
Participants will be assigned at Day 1 to one of the following 3treatment arms in a ratio of
1:1:1. The treatment arms include:
Arm 1: hydroxy chloroquine (HCQ) plus azithromy cin (AZI) placebo
HCQ: 600mg o.d.as loading dose (Day  1)followed by  200 mg t.i.d. The time 
between the 600mg loading dose and first 200mg dose should be 8- hours (not to 
exceed 12 hours)
AZI placebo o.d. The loading dose of AZI placebo (Day  1) should be taken 4 hours 
after loading dose of HCQ 
Novartis Confidential Page 29of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Arm 2: hydroxy chloroquine (HCQ) plus azithromy cin(AZI)
HCQ: 600 mg o.d. as a loading dose (Day  1) followed by  200 mg t.i.d.. The time 
between the 600mg loading dose and first 200mg dose should be 8- hours (not to 
exceed 12 hours)
AZI: 500 mg as a loading dose (Day  1)followed by  250 mg o.d. D ay 2 –Day 5. The 
500mg loading dose of AZI (Day  1) should be taken 4 hours after loading dose of 
HCQ 
Arm 3: hydroxy chloroquine (HCQ) placebo plus azithromy cin(AZI) placebo
HCQ placebo o.d. (Day  1) followed by  HCQ placebo t.i.d. The time between the fir st 
and the second dose should be 8 hours (not to exceed 12 hours) to match other 
treatment arms. 
AZI placebo o.d. The loading dose of AZI placebo (Day  1) should be taken 4 hours 
after loading dose of HCQ placebo
6.1.3 Treatment duration
The total treatment duration of hydroxychloroquine is10 days. The approach to include a 
loading dose on Day 1  is preferred in order to rapidly  reach higher target tissue drug 
concentrations. The total treatment duration of azithromy cin will be 5 day s.
In case a participant is discharged prior to Day 10,they may complete study  treatment as 
planned, at home ,until Day 10 if QTcF ≤ 480 ms at the time of discharge based on the local 
ECG data . Otherwise, treatment will be discontinued at the time of discharge .
6.2 Other treatment(s)
6.2.1 Concomitant therapy
All relevant medications, procedures, and significant non-drug therapies ( e.g. blood 
transfusions) administered after the participant was enrolled into the stud y must be recorded on 
the appropriate Case Report Forms (CRFs) .
6.2.1.1 Standard of care for COVID -19 disease
All participants will receive best standard of care as background therap y. Although there are no 
specific therapies approved for thetreatment ofCOVID -19, participants with moderate and 
severe disease are exp ected to receive supportive care as dictated b y local treatment guidelines. 
Depending on the disease severity , supportive care may include the use of oxygen 
supplementation, antibiotic prophy laxis and other concomitant medications for comorbidities, 
ventil ator support, and intensive care management for disease progression.
The study  permit sany of standard of care for COVID -19 disease except the medication slisted 
in the prohibited medication in Table 6-2.
6.2.2 Rescue medication
Resc ue therapy  may  be used at the discretion of the Investigator if there is evidence of clinical 
deterioration of COVID -19disease and intervention with a rescue therapy is required beyond 
the standard of care measures.
Novartis Confidential Page 30of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
6.2.3 Prohibited medication
Table 6-2 Prohibited medication
Medication Prohibition period
Any drug known to prolong QTc interval
(See https://crediblemeds.org/ for details as 
well as protocol supplementary guidance)Within 5 half-lives before screening and through outthe 
study
Antiviral agent s
e.g. remdesivir, oseltamivir , interferon, 
lopinavir/ ritonavir or other protease 
inhibitors, chloroquine, nitazoxanide, 
convalescent COVID19 serum or anti -
SARS -COV -2 immunoglobulinsUp to Day 15 or until discharge whichever earlier
Except in the case these are needed to be used as 
rescue therapy (see Section 6.2.2 )
Newly approved COVID- 19 therapies (if 
any available since issuing the protocol)Within 5 half -lives or 30 days of screening whichever 
is longer ,andup to Day 15or until discharge 
whichever earlier .
Except in the case these are needed to be used as 
rescue therapy (see Section 6.2.2 )
6.3 Participant numbering, treatment assignment, randomization
6.3.1 Participant numbering
Each participant is identified in the study  by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant 
throughout his/her participation in the trial. A new Participant No. will be assigned at every  
subsequent enrollment if the participant is re-screened. The Participant No. consists of the 
Center Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential 
participant number suffixed to it, so that each participant’s participation is numbered uniquely 
across the entire database. Upon signing the informed co nsent form, the participant is assigned 
to the next sequential Participant No. available.
Participant numbers are assigned when the site creates the first entry  for the participant in the 
CRF, therefore CRF entry  must be created prior to contacting the Interactive Response 
Technology  system.
6.3.2 Treatment assignment, randomization
At Day 1,all eligible participants will be randomized via Interactive Response Technology  (IRT) 
to one of the treatment arms. The unblinded pharmacist will contact the IRT after confirmation 
from the investigator or his/her delegate that the participant fulfills all the inclusion/exclusion 
criteria. The IRT will assign a randomization number to the participant, which will be used to 
link the participant to a treatment armand the unblinded pharmacist will be provided with the 
treatment arm assigned to the participant.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from participants and investigator staff. A 
participant randomization list will be produced by the IRT provider using a validated system 
Novartis Confidential Page 31of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
that automates the random assignment of participant numbers to randomization numbers. These 
randomization numbers are linked to the different treatment a rms. 
The randomization scheme for participants will be reviewed and approved by  a member of the 
Randomization Office.
The unblinded pharmacist MUST NOT communicate the information of treatment arm to 
anyone who is involved to the study  (site personnel including the investigator, participant, 
sponsor). If accidentally  communicated to anyone, Novartis local monitor should be notified 
and the study  treatment should be discontinued.
6.4 Treatment blinding
The study  will be double -blind as both Investigator and participants will be blinded to the study 
medication from the time of randomization until the final database is locked after the last 
follow -up visit at Day  40.
Open label supply  of investigational treatments (HCQ and AZI) and similar appearance placebo 
will be provided at site to the unblinded site pharmacist.
Unblinding will occur in the case of participant emergencies and will only be undertaken bythe 
investigator (See Section 6.5.2 ).The unblinded pharmacist is not involved inemergency 
unblinding.
Designated Novartis clinical trial team members will be unblinded following data extraction for 
the primary  endpoint analy sis (Day  15) to perform the anal ysis. 
Other Novartis team members, I nvestigators and participants will remain blinded to individual 
treatment allocation until final database lock. In addition ,for the purposes of the Data 
Monitoring Committee (DMC) analy sis, there will be unblinded Independent Statisticians and 
Programmers in charge of DMC reporting activities.
6.5 Additional treatment guidance
6.5.1 Treatment compliance
The unblinded pharmacist must record all study  treatment dispensed in the Drug Accountability 
Log, which must not be shared with blinded members of the site staff .
The site staff must record the date and time of dosing for each medication in the source 
documents for the participant.
In the case that a participant is discharged prior to Day 10, they should be instructed on the 
dosing requirements and contacted at Day 10 to confirm compliance. The participant must also 
be instructed to contact he investigator if he/she is unable for any reason to take the study 
treatment as prescribed.
Compliance will be assessed by the investigator and/or study  personnel at each visit using the 
information provided by the participant. This information should be captured in the source 
documents.
Novartis Confidential Page 32of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
6.5.2 Emergency  breaking of assigned treatment code
Emergency  code breaks must only be undertaken when it is required to in order to treat the 
participant safel y. Blinding codes ma y also be broken after a participant discontinues treatment 
due to disease progression if deemed essential to allow the investigator to select the participant’s 
next treatment regimen, and after discussion and agreement with the sponsor. Most often, study 
treatment discontinuation and knowledge of the possible treatment assignments are sufficient 
to treat a study  participant who presents with an emergency  condition. Emergency  treatment 
code breaks are performed using the IRT. When t he investigator contacts the s ystem to break a 
treatment code for a participant, he/she must provide the requested participant identify ing 
information and confirm the necessity  to break the treatment code for the participant. The 
investigator will then receive details of the investigational drug treatment for the specified 
participant and a fax or email confirming this information. The system will automatically  inform 
the Novartis monitor for the site and the study  team that the code has been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investigator 
will provide:
protocol number
name 
participant number
In addition, oral and written information must be provided to the participant on how to contact 
his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time.
6.6 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs section.
As per the treatment assigned to the participant, the unblinded pharmacist will select the study 
treatment to be dispensed to the participant. 
6.6.1 Handli ng of study treatment and additional treatment
6.6.1.1 Handling of study  treatment
In order to ensure treatment blinding study treatment must be received , stored in a secure 
location and dispensed only by an unblinded pharmacist. A ll study  treatment must be stored
according to the instructions specified on the labels .
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective Novartis C ountry  Organization Quality  Assurance.
Medication label s will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the participant except for the medication number .
Novartis Confidential Page 33of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
An accurate record of the shipment and dispensing of study  treatment should be maintained in 
a drug accountability  log. Monitoring of drug accountability  will be performed by monitors 
during site visits or remotely  and at the completion of the trial. 
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of the completed drug 
accountability  log to the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
7 Informed consent procedures
Eligible participants may only be included in the study  after providing (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent.
If applicable, in cases where the participant's representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent 
possible given his/her understanding. If the participant is capable of doing so, he/she must 
indicate agreement b y personally signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the participant source documents.
Novartis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by the 
investigator must be agreed by  Novartis before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drugscanbe 
found in the USPI /applicable labelling information . This information will be included in the 
participant informed consent and should be discussed with the participant during the study  as 
needed. Any new information regarding the safety  profile of the investigational drugsthat is 
identified between labelling updates will be communicated as appropriate, for example, via an 
investigator notification or an aggregate safet y finding. New information might require an 
update to the informed consent and then mu st be discussed with the participant.
The following informed consents are included in this study :
Main study  consent, which also includes:
A subsection that requires a separate signature for the ‘Optional Consent for 
Additional Research’ to allow future research on data/samples collected during this 
study
As applicable, Pregnancy Outcomes Reporting Consent for female subjects or the female 
partners of an y male subjects who took study treatment
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
Novartis Confidential Page 34of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Male participants must be informed that if a fema le partner becomes pregnant while he is 
enrolled in the study , contact with the female partner will be attempted to request her consent 
to collect pregnancy  outcome information.
A copy of the approved version of all consent forms must be provided to Novart isafter IRB/IEC 
approval.
8 Visit schedule and assessments
The Assessment Schedule (Table 8 -1)lists all of the assessments when they are performed. All 
data obtained from t hese assessments must be support ed in the participant’s source 
documentation.
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
(Table 8-1)or as close to the designated day/time as possible. Missed or rescheduled visits 
should not lead to automatic discontinuation.
Novartis Confidential Page 35of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Table 8-1 Assessment schedule
Period Screening Treatment Post treatment 
Visit Name Screening Day 1Day 2Day 4Day 6Day 8Day 10/ 
early  
dischargeDay 15 / early  
withdrawal 
Primary  EndpointEnd of 
study
follow upUnscheduled1
(report 
assessments as 
applicable) 
Days -3 to 0 1 2 4 6 8 10 15 40 -
Informed consent X
Inclusion / Exclusion criteria X X
Demography X
Medical history/current medical conditions X
Chest imaging X3X3
Randomization X
Drug dispensation and administration X
Pregnancy test (serum and urine dipstick) X
Physical Examination, vital signs and body 
measurements2 X X X X X X X X
SARS -COV -2 test X4X X X X
Electrocardiogram (ECG) X X5X X X6X6X
Laboratory assessments (hematology, 
chemistry, urinalysis, )7 X X X X3
Biomarker plasma and serum X X X
Prior and concomitant medications X 
Adverse Events X
Study completion information X
X Assessment to be recorded in the clinical database or received electronically from a vendor, 1All assessments for unscheduled visits are optional,2Height and weight 
collected at screening only, 3If available record findings, 4If results of a previously performed test within 4 days prior to planned randomization are available this does not 
need to be repeated for screening 5 pre-dose and 4 hours post dose, 6If required in the opinion of the Investigator. 7Hematology: Hct,Hgb, PLT , RBC ,WBC, different ial 
WBC count; Chemistry: ALP , ALT , AST, Ca, Mg, K, c reatinine, direct and t otal bilirubin, BUN , glucose , troponin (I or C), CPK,  

Novartis Confidential Page 36of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
8.1 Screening
Screening
The screenin g perio d will be a maximum of 4 days, and is used to check the participant ’s
eligibility  after obtaining informed consent and prior to the randomization on Day 1. The 
assessments requir edat screening are summarized in Table 8-1. If all eligibil ity criteria are 
confirmed screening and randomization may  occur on the same day .
8.1.1 Information to be collected on screening failures
Participants who consent edandaresubsequentl y found to be ineligible prior to randomization 
will be considered a screen failure. The reason for screen failure should be recorded on the 
appropria te Case Report Form. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for screen failure participants. No other data 
will be entered into the clinical database for participants who are screen failures, unless the 
participant experienced a serious adverse event during the screening phase (see SAE section for 
reporting details). If the participant fails to be randomized, the IRT must be notified within 2 
days of the screen fail that the participant was not ra ndomized.
Participants who are randomized and fail to start treatment, e.g. participants randomized in error, 
will be considered an early  terminator. The reason for earl y termination should be recorded on 
the appropriate Case Report Form.
8.2 Participant demographics/other baseline characteristics
All baseline assessments must be performed prior to first study  treatment administration. These 
may be in the screening period (e.g. demographics) or at the randomization visit, depending on 
the assessment.
8.2.1 SARS-COV- 2 testing
Respiratory  tract specimen (e.g.nasophary ngeal swab, mid-nasal swab) will be taken for SARS -
COV -2 PCR or rapid test and analy zed locall y whether negative (or below LLOQ) or not to 
determine eligibility .If results of a previously  perfor med test within 4 days prior to planned 
randomization date are available this does not need to be repeated for screening.
8.2.2 Demographic information
Demographic data to be collected at screening on all participants include: year of birth or age, 
gender, race, ethnicity  and child -bearing potential (for females onl y).
Any relevant medical history  including date of onset of COVID -19disease symptoms, date of 
diagnosis of COVID -19 disease protocol solicited medical history , and/or current medical 
conditions before obtaining informed consent will be recorded in the Medical History  CRF. 
Significant findings that are observed after the participant has provided informed consent and 
that meet the definition of an AE must also be recorded in the AE CRF. Whenever possible , 
diagnoses and not s ymptoms will be recorded.
Novartis Confidential Page 37of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
8.2.3 Prior and concomitant medications
Relevant prior and concomitant medications will be captured at the screening visit, and updated 
at the baseline visit. Any changes to the ongoing medications or any new concomitant 
medications will be recorded in CRF on an ongoing basis throughout stud y participation.
 
 
8.2.5 Other baseline characteristic s
Baseline characteristic data to be collected for all participants listed below :
ECG, vital signs, height and body  weight

date and matrix (nasophary ngeal, orophary ngeal, other) of SARS -COV -2 test
physical examination (to be recorded i n source documents only )
chest imaging (date and method of assessment – x- ray or CT scan, normal or abnormal –
any clinically  relevant findings to be reported in medical history )
Any other testing required for inclusion/exclusion criteria
8.3 Efficacy
8.3.1 COVID -19Participant status
The following details on the participants’ status will be collected in the at Baseline and hospital 
discharge at a minimum, in addition any change in status must be reported in the CRF :
Hospitalization (including dates of admission and discharge* or ready  for discharge )
ICU stay  (including dates of admission** and discharge ***)
Pre-morbid s upplemental oxy gen requirements and its volu me if y es(start and stop dates, 
volume : L)
Mechanical ventilation requirements (start and stop dates)
Participant survival status (i.e. death)
* If a participant is unable to be discharged due to administrative reasons, then the date that the 
participant, in the opinion of the investigator, is ready to be disch arged (i.e. read y for discharge 
as evidenced b y normal body temperature and respiratory rate, and stable oxygen saturation on 
ambient air or ≤2L supplemental oxygen) should be reported in the hospitalization status for 
date of discharge.

Novartis Confidential Page 38of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
** In the case that a participant cannot be admitted to the ICU, even if the participant’s condition 
is severe enough in the opinion of the investigator (e.g. due to administrative reasons under the 
current circumstances), this is also considered under admission and date of ICU admission 
should be reported
***If a participant is unable to be discharged from I CU due to administrative reasons, then the 
date that the participant, in the opinion of the investigator, is ready  to be discharged should be 
reported in the ICU status for date of discharge.
 
 
 
 
8.3.2 SARS-
COV- 2 testing
At each SARS -COV -2 testing time point post screening detailed in Table 8-1a respiratory  tract 
specimen (nasophary ngeal swab) will be taken for SARS -COV -2 PCR testing. This sample will 
be analyzedat a specialist virology lab to determine whether negative (or below LL OQ) or not .
An additional sample may be collected andsent to the central lab for future quantitative analysis.
Additional details on sample collection and shipp ing are provided in the laboratory  manual.
In order to maintain consistency , every  effort should be made to use the same sample site (i.e. 
nostril) for all post baseline assessments in individual participants.
8.3.3 Appropriateness of efficacy  assessments
Effica cy assessments are assessments of standard supportive care required to treat COVID -19 
disease. Events that are clearl y consistent with the expected pattern of progression of the 
underly ing disease should notbe recorded as adverse events (with the exceptio n of death due 
to COVI D-19 disease progression). These data will be captured as efficacy  assessment data 
only.

Novartis Confidential Page 39of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
8.4 Safet yand tolerability
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.
For details on AE collection and reporting, refer to AE section.
8.4.1 Physical examination 
Information for all phy sical examinations must be included in the source documentation at the 
study  site. Significant findings that are present prior to informed consent being obtained must 
be included in the Relevant Medical History /Current Medical Conditions CRF. Significant 
findings made after informed consent is given which meet the definition of an Adverse Event 
must be recorded on the Adverse Event screen of the participant s CRF.
8.4.2 Vital signs and body  measurements
Systolic and diastolic blood pressure (mmHg) ,pulse rate (bpm) , will be recorded .Peripheral 
oxygen saturation (SpO2, %) should be also measured at the same time as vital signs , height in 
centimeters (cm) will be reported at screening visit only .  
Weight in pounds (lbs) or kilograms (kg), and body temperature (including method of collection) 
in Centigrade (°C) or Fahrenheit (°F) will be recorded.
8.4.3 Laboratory  evaluations
Laboratory  test will be conducted as per Table 8-1by local lab .Details on theparameter sare
listed below in Table 8-2.
Clinically  significant abnormal results for hematology , chemistry  and urinaly sis will be 
reported in the laboratory  results CRF and as an AE, otherwise all these results will be kept in 
the source document sand will not need to be recorded in CRF .  
Table 8
-2 Laboratory  parameters (local lab)
Test Category Test Name
Hematology Hematocrit , hemoglobin, platelets, red blood cells, white blood cells
(WBC), absolute d ifferential WBC count (b asophils, eosinophils, 
lymphocy tes, monocy tes, neutrophils, bands , other)
Chemistry Alkaline phosphatase, alanine transaminase ( ALT), aspartate 
aminotransferase ( AST), calcium, magnesium , potassium, creatinine, 
direct bilirubin , total bilirubin, blood u rea nitrogen (BUN),  glucose , 
troponin (I or C as available) , CPK
Urinalysis (dipstick) Specific gravity, pH, protein, glucose and blood
Pregnancy Test Serum / Urine pregnancy test
8.4.4 Electrocardiogram (ECG)
ECGs (preferabl y 12-lead) must be recorded after 10 minutes rest in the supine position to 
ensure a stable baseline. The preferred sequence of cardiovascular data collection during stud y 

Novartis Confidential Page 40of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
visits is ECG collection first, followed by vital signs. The Fridericia QT correction formula 
(QTcF) should be used for clinical decisions.
On Day 1 an ECG must be performed pre -dose and at 4 hours post dose.
Single ECGs (preferabl y 12-lead) will be collected using the sites own ECG machines and key 
parameters and the original trace available within the source data. A copy of the local tracing 
will be sent to a central ECG reader for additional safet y evaluations. Any identifier details must 
be redacted e.g. subject initials, date of birth prior to sending to the central reader.
If participants are monitored by  continuous telemetry , an assessment should be reported in the 
CRF for one time point on day s when ECG monitoring is required and a copy  of ECG tracing
for this time point sent to the central ECG reader. In case of clinically  significant findings the 
unscheduled visit can be used to report findings and an adverse event form completed if 
applicable.
For any ECGs with potential participant safet y concerns, two additional ECGs (preferabl y 12-
lead) must be performed to confirm the safety  finding. A local monitoring or review process 
should be in place for clinically  significant ECG findings throughout the study . Clinically 
significant abnormalities must be recorded on the CRF as either medical history /current medical 
conditions or adverse events as approp riate.
Given the known QT prolonging effect and treatment regimen of both HCQ and AZ I, measure 
ECG until Day  4, then if required b y the investigator from Day 6.
Please also refer to the cardiac safet y monitoring Section 10.2.1 for additional details.
8.4.5 Pregnancy  test
All pre-menopausal women who are not surgicall y sterile will have urine pregnancy  testing and 
serum pregnancy  test at screening as per Table 8 -1.
If the result of urine pregnancy  test is positive, the patient must not be randomized and the result 
confirmed by the serum pregnancy  test result .If the result of the serum pregnancy  test is positive,
the pa rticipant must be considered as a screen failure.
A positive pregnancy  test during the study  requires immediate discontinuation from study  drug. 
The participant must be followed to understand the outcome of the pregnancy. Refer to Section
10.1.4 for details on pregnancy  reporting .
8.4.6 Appropriateness of safety  measurements
The safet y assessments selected are appropriate for this protocol, which utilizes a marketed 
compound where the safety  profile has been established. The assessments are relevant to the 
critical care setting and will enable determination of therapeutic response in this setting.
Novartis Confidential Page 41of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
8.5 Additional assessments
8.5.1 Unsch eduled assessments
In the case of clinically  significant abnormalities, safet y concerns required repeat testing or if 
additional assessments need to be performed, information should be reported in the relevant 
CRF page using the Unscheduled visit pages.
8.5.2 Assessments pre and post hospital discharge
In the case that a participant is discharged from hospital during the study ,the following 
guidelines must be followed:
If the participant is discharge prior to Day  10, a ssessments for Day10/early  discharge visit 
should be completed pr ior to discharge
If the participant continues treatment up to Day 10 at home, guidelines in Section 6.1.3
should be followed . The site must contact the participant to assess compliance, and report 
any dose interruptions and stop dates of treatment, adverse events and relevant 
concomitant medications in the CRF
Day 15andDay 40 visits may  be performed via phone call, an onsite visit is not 
mandated, at a minimum COVID -19 participant status, adverse events and relevant 
concomitant medications, and study  completion status (as applicable) must be assessed. 
In the case that the participant is still hospitalized for either or both Day  15 and Day  40 
visits additional assessments requested in Table 8-1if assessed, as per local practices, may  
be reported in the relevant CRF pages.
8.5.3 Biomarkers
Serum and plasma will be stored for future biomarker analy sis and will be covered by the 
secondary  data use informed consent provided at time of screening .
Sample(s) will be collected at the time point(s) defined in the Assessment Schedule ( Table 8-1)
when possible.
Follow instructions for sample collection, numbering, processing, and shipment provided in the 
laboratory  manual.
9 Study  discontinuation and completion
9.1 Discontinuation and completion
9.1.1 Study treatment discontinuation and study discontinuation
Discontinuation of study treatment for a participant occurs when study treatment is stopped 
earlier than the protocol planned duration and can be initiated by either the participant or the 
investigator . The investigator must discontinue study  treatment for a given participant if, he/she 
believes that continuation would negat ively impact the participant's well -being.
If, for any reason , one of the study  drugs should be stopped prior to day  5, then the both study  
drugs should be discontinued and the reason for discontinuation reported in the CRF.   
Novartis Confidential Page 42of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Study  treatment must be discontinued under the following circumstances:
Participant/guardian decision
Pregnancy
Use of prohibited treatment as per recommendations in the prohibited treatment section
Any situation in which study  participation might result in a safet y risk to the participant
including cardiac events (please refer to Section 10.2 and Section 16 for additional safety  
monitoring criteria) 
Following emergency  unblinding
Unsati sfactory  therapeutic effect
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consideration the participant’s overall status, prevents the participant from continuing 
participation in the study
If discontinuation of study  treatment occurs, the investigator should record theprimary  reason 
for the participant’s premature discontinuation.
Participants who discontinue study  treatment or who decide they do not wish to participate in 
the study  further should NOT be considered withdrawn from the study  UNLESS they withdraw 
their consent (see 'Withdrawal of I nformed Consent' section). Where possi ble, they should be
assess ed as per visit schedule in Table 8-1.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
New / concomitant treatments
Adverse Events / Serious Adverse Events
The investigator must also contact the IRT to register the participant’s discontinuation from 
study  treatment.
If discontinuation occurs because treatment code has been broken, please refer to Emergenc y 
breaking of treatment code section.
9.1.2 Withdrawal of informed consent
Participants may  voluntarily  withdraw consent to participate in the study  for any  reason at any 
time. Withdrawal of consent occurs onl y when a part icipant:
Does not want to participate in the study  anymore,
and
Does not want an y further visits or assessments
and
Does not want an y further study related contacts
In this situation, the investigator should make a reasonable effort to understand the prima ry 
reason for the participant’s decision to withdraw his/her consent and record this information.
Where consent to the use of personal and coded data is not required, participant therefore cannot 
withdraw consent. They  still retain the right to object to the further use of personal data.
Novartis Confidential Page 43of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the participant are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  discontinuation. A final 
evaluation at the time of the participant’s study  discontinuation should be made as detailed in 
the assessment table.
Novartis /Sponsor will continue to retain and use all research results (data) that have alread y 
been collected for the study  evaluation.
9.1.3 Lost to follow -up
For participants whose status is unclear because they fail to appear for study  visits without 
stating an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the participant, e.g. dates of 
telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due diligence has been completed or until the end of the study .
9.1.4 Early  study termination by  the sponsor
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the participant should be seen as soon as possible and treated as a prematurely  withdrawn 
participant . Adverse events and laboratory  findings will be continuall y reviewed during the 
study .New enrollment and/or dosing for a treatment arm or study  overall may be paused in case 
of safet y concerns that are suspected to be related to study drug, including:
>2 participants with Torsade de Pointes or Ventricular Tach ycardia associated with
QTcF > 500 msec and QTcF prolongation > 60 msec
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the participant’s interests. The 
investigator will be responsible for informing the Institutional Review Board/Independent 
Ethics Committee (I RBs/IECs) of the earl y termination of the trial.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last participant finishes their Study  Completion visit 
and any repeat assessments associ ated with this visit have been documented and followed- up 
appropriatel y by the Investigator or, in the event of an early study termination decision, the date 
of that decision (e.g. Each participant will be required to complete the study  in its entirety  and
thereafter no further study  treatment will be made available to them) .
All randomized and/or treated participants should have a safet y follow -up call conducted 30 
days after last administration of study  treatment. The information collected is kept as source 
documentation. All SAEs reported during this time period must be reported as described in 
Section 10.1.3. Documentation of attempts to contact the participant should be recorded in the 
source document ation.
There is no planned post- study -treatment in this study .
Novartis Confidential Page 44of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a clinical 
investigation participant after providing informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual participant and 
identify ing adverse events.
Novartis qualified medical personnel will be readily  available to advise on trial r elated medical 
questions or problems.
The occurrence of adverse events must be sought by non-directive questioning of the participant 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the participant during or between visits or through physical examination findings, laboratory 
test findings, or other assessments .
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by the following information (as far as possible) (if the event is serious refer to 
Section 10.1.2):
1.The severit y grade: 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.Its relationship to the study  treatment .If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causal ity 
will usually  be ‘Not suspected.’ The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single participant
3.Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported
4.Whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.Action taken regarding study  treatment.
All adverse events must be treated appropriatel y. Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Novartis Confidential Page 45of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Drug interrupted/withdrawn
6.Its outcome (i.e. recovery  status or whether it was fatal)
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history of the participant.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study  treatment.
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drugscan be found in the 
USPI /applicable labelling information.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (pl ease refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing t he informed consent
social reasons and respite care in the absence of any  deterioration in the participant’s 
general condition
Novartis Confidential Page 46of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not result ing in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the participant or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised indeciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the participant or might 
require intervent ion to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant.” Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospitalization or development of dependency  or abuse (please refer to the ICH-
E2D Guidelines).
All new malignant neoplasms will be assessed as serious under “medicall y significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the 
study  indication.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred. 
10.1.3 SAE reporting
To ensure participant safety , every  SAE, regardless of causalit y, occurring after the participant 
has provided informed consent and until 30 days after the last study  visitmust be reported to 
Novartis safet y within 24 hours of learning of its occurrence. Detailed instructions regarding 
the submission process and requirements are to be found in the investigator folder provided to 
each site.
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurrin g at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously  documented in the Package Insert and is thought to be related to 
the study  treatment, a CMO & PS Department associate may urgently  require further 
information from the investigator fo r health authority reporting. Novartis /Sponsor may need to 
issue an Investigator Notification (IN) to inform all investigators involved in any study with the 
same study  treatment that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory  requirements in participating countries.
Any SAEs experienced after the 30 day safety follow up period should only be reported to 
Novartis Safet y if the investigator suspects a causal relationship to study  treatment.
Novartis Confidential Page 47of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
10.1.4 Pregnancy  reporting
Pregnancies
If a female trial participant becomes pregnant, the study  treatment should be stopped, and the 
trial participant must be asked to read and sign pregnancy  consent form to allow the Study 
Doctor ask about her pregnancy . To ensure participant safet y, each pregnancy  occurring after 
signing the informed consent must be reported to Novartis /Sponsor within 24 hours of learning 
of its occurrence. The pregnancy  should be followed up to determine outcome, including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any 
birth defects, congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to the Novartis /Sponsor Chief 
Medical Office and Patient Safety  (CMO&PS). Pregnancy  follow -up should be recorded on the 
same form and should include an assessment of the possible relationship to the study  treatment
any pregnancy  outcome. Any  SAE experienced during pregnancy  must be reported.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
10.1.5 Reporting of study treatment errors includ ing misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or 
consumer (EMA definition).
Misuse refers to situati ons where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
Novartis Confidential Page 48of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
10.2 Additional Safety  Monitoring
10.2.1 Cardiac safety  monitoring
In case of QTcF > 500 msec and QTcF prolongation > 60 msec from baseline , please take 
the following steps :
Temporaril y interrupt study  treatment
Assess the quality  of the ECG recording and the QT value and record two additional 
ECG tracings to confirm the values
Determine the serum electroly te levels (in particular hy pokalemia, hy pomagnesemia
and/or hy pocalcemia ). If abnormal, correct abnormalities before resuming study  
treatment.
Review concomitant medication use for other causes for QT prolongation (refer to 
qtdrugs.org for k nown QT prolonging drugs) and for drugs with the potential to 
increase the risk of drug exposure of study  drugs
Check the dosing schedule and treatment compliance
Increase cardiac monitoring as indicated, (consider continuous telemetry  monitoring )
until the QTcF returns to ≤ 480 msec
If QTcF is  ≤ 480 msec prior to the next dose, continue dosing with another ECG 
collected 4 hrs post dose 
If QTcF remains > 480 msec prior to the next dose discontinue study  treatment for the 
participant permanently
In case of persistent QTcF > 500 msec and QTcF prolongation > 60 msec from baseline 
and/or documented new onset arrhythmia (e.g. Torsade de Pointes, Ventricular 
Tachycardia) or syncope -discontinue treatment for the pa rticipant and request evaluat ionby 
a cardiol ogist.
Please refer to Append ix 1for notable vital signs.
Local practices should be followed to ensure participant safety for Liver and Renal 
monitoring, in addition below are suggested guidelines for safety monitoring .
10.2.2 Liver safety monitoring
To ensure participant safety  and enhance reliability  in determining the hepatotoxic potential of 
an investigational drug, a standardi zed process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 16-1in Append ix 2for complete de finitions of liver laboratory  triggers.
Once a participant is exposed to study  treatment, it is suggested that every  liver event defined 
in Table 16-1should be followed up by the investigator or designated personnel at the trial site, 
as summarized below. Additional details on actions required in case of liver events are outlined 
in Table 16-2.Repeat liver chemistry  tests (i.e. ALT, AST, TBL, ALP and G-GT) to confirm 
elevation.
These liver chemistry  repeats should be performed using the local laboratory  used by the site. 
Repeated laboratory  test results must be reported as appropriate.
Novartis Confidential Page 49of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
If the initial elevation is confirmed, close observation of the participant will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to the Discontinuation of study  treatment 
section), if appropriate
Causalit y assessment of the liver event
Thorough follow -up of the liver event should include based on investigator’s discretion :
serology  tests, imaging and pathology  assessments, hepatologist’s consultancy ; 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  
of concomitant drug use, exclusion of underly ing liver disease
All follow -up information and procedures performed must be recorded as appropriate in the 
CRF.
10.2.3 Renal safety  monitoring
Once a participant is exposed to study  treatment, the following two categories of abnormal renal 
laboratory  alert values should be assessed during the study  period:
Serum creatinine increase ≥ 50% compared to baseline during normal h ydration status
Any one of the following:
Urine protein- creatinine ratio (PCR) ≥1g/g or ≥100 mg/mmol, OR
New onset dipstick proteinuria ≥ 3+, OR
New onset dipstick hematuria ≥ 3+ (after excluding menstruation, UTI, extreme 
exercise, or trauma)
Abnormal renal event findings must be confirmed after ≥24 hours but ≤ 5 days after first 
assessment .
Once a participant is exposed to study  treatment, renal laboratory  alerts or renal safet y events 
should be monitored and followed up by the investigator or designated trial staff according to 
the local practice, guidance is summariz ed in Table 16-4in Append ix 2.
10.2.4 Data Monitoring Committee
This study  will include an internal data monitoring committee (DMC) , which will function 
independentl y of all individuals associated with the conduct of this clinical trial, including the 
site investigators participating in the study .Specific details regarding composition, 
responsibilities, data monitoring and meeting frequency , documentation of DMC reports, 
minutes and recommendations will be described in a separate DMC charter.
11 Data Collection and Database management
11.1 Data collection
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verification. 
Novartis Confidential Page 50of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Designated investigator staff will enter the data required by the protocol and defined in the 
assessment schedule (Table 8-1)into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs, 
allow modification and/or verification of the entered data b y the investigator staff.
The investigator/designee is responsi ble for assuring that the data (recorded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry  and updates are performed in a timely  manner. 
The Investigator must certify  that the data entered are complete and accurate.
This study  may also incorporate electronic technology  (eSource DDE) to capture source 
documents and source data electronicall y, consistent with final (CDER 2013 ) FDA guidance 
regarding electronic source and Regulations related to the main tenance of adequate participant 
case histories ( 21 CFR 312.62(b) ). 
A Novartis representative will review the protocol and data capture requirements (i.e. eSource 
DDE and/or eCRFs) with the investigators and their s taff.
After final database lock, the investigator will receive copies of the participant data for 
archiving at the investigational site.
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verif ication.
11.2 Database management and quality  control
Novartis personnel will review the data entered by investigational staff for completeness and 
accuracy . Electronic data queries stating the nature of the problem and requesting clarification 
will be created for discrepancies and missing values and sent to the investigational site via the 
EDC sy stem. Designated investigator site staff are required to respond promptly to queries and 
to make an y necessary changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employ s the Anatomical 
Therapeutic Chemical classification system. Medical history /current medical conditions and 
adverse events will be coded using the Medical Dictionary  for Regulatory  Activities (MedDRA) 
terminology .
Dates of screenings, randomizations, screen failures, as well as randomization codes and data 
about all study  treatment (s) dispensed to the participant will be tracked using an Interactive 
Response Technology  (IRT). The system will be supplied by a vendor, who will also manage 
the database. The data will be sent electronicall y to Novartis /Sponsor (or a designated CRO) at 
specific timelines.
Each occurrence of a code break via I RT will be reported to the clinical team and monitor. The 
code break functionality will remain available until study  shut down or upon request of 
Novartis /Sponsor .
Novartis Confidential Page 51of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
11.3 Site monitoring
Before study  initiation, at an initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and data capture requirements (i.e. eSource DDE and/or 
CRFs) with the investigators and their staff. During the study , Novartis employ s several 
methods of ensuring protocol and GCP compliance and the quality /integrity  of the sites’ data. 
The field monitor will check the completeness of participant records, theaccuracy  of data 
capture / data entry , the adherence to the protocol and to Good Clinical Practice, the progress 
of enrollment, and to ensur e that study  treatment is being stored, dispensed, and accounted for 
according to specifications. Key  study personnel must be available to assist the field monitor in 
conducting these activities. Continuous monitoring of each site’s data will be performed 
throughout the conduct of the stud y. Additionall y, a central anal ytics organization may anal yze 
data and identify  risks and trends for site operational parameters, and provide reports to 
Novartis clinical teams to assist with trial oversight . The investiga tor must maintain source 
documents for each participant in the study , consisting of case and visit notes (hospital or clinic 
medical records) containing demographic and medical information, laboratory  data, 
electrocardiograms, and the results of any  other tests or assessments. All information on CRFs 
must be traceable to the respective source documents.  The investigator must also keep the 
original informed consent form agreed by the participant and/or legal representative (a copy  is 
given to the participant ).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Novartis monitoring standards require 
verification for the presence of all informed consents, adherenc e to the inclusion/exclusion 
criteria, documentation of SAEs, and of data that will be used for all primary  variables. 
Additional checks of the consistency  of the source data with the CRFs are performed according 
to the study -specific monitoring plan. No information in source documents about the identity 
of the participants will be disclosed.
12 Data analy sis and statistical methods
The primary  analysis time point is Day 15.  The analyses of efficacy  and safet y described in 
this protocol will occur when all participants in the study  have completed their final study  visit 
at Day  40.
Unless otherwise specified , descriptive summaries for c ategorical data will include frequencies 
and percentages, and continuous data will be presented with mean, standard deviation, median, 
minimum, and maximum. For selected parameters, 25th and 75th percentiles may also be 
presented.
Differences, relative ratios (RR) or odds ratios (OR) for the comparisons between the two 
treatment arms will be presented with 2-sided 95% confidence interval (CI). P-values will be 
presented onl y if a formal hy pothesis test is performed.
Any data analy sis carried out independently  by the investigator should be submitted to Novartis 
before publication or presentation.
Novartis Confidential Page 52of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
12.1 Analysis sets
The Randomi zed Analysis Set (RAS) consists of all randomized participants regardless of 
receiving stud y treatment .
The Full Anal ysis Set (FAS) comprises all participant to whom study  treatment has been 
assigned by randomization excluding mis-randomized participants . Mis-randomized 
participants are defined as cases where IRT contact ismade by the Investigator/qualified site 
staff either prematurel y or inappropriatel y prior to confirmation of the participant’s final 
randomization eligibility  and treatment is not administered to the participant. According to the 
intent to treat principle, participants will be analyzed according to the treatment they have been 
assigned to during the randomization procedure.
The Safet y Set (SAF) includes all participants who received at least one dose of study  treatment. 
Participants will be analy zed according to the study  treatment received , where treatment 
received is defined as the randomized/assigned treatment if the participant took at least one dose 
of that treatment or the first tr eatment received if the randomized/assigned treatment was never 
received.
The anal ysis of the primary  objective and all other efficacy  variables will be performed on the 
FAS.  The Safety  Set will be used in the anal ysis of all safet y variables.
12.2 Participant demographics and other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively by treatment group for all study  participants in the FAS and safet y 
set. Participant demogra phic and baseline characteristics will include: age, sex, race, ethnicity , 
height, weight, BMI, oxygen saturation (SpO2), duration of symptom onset torandomization, 
duration from hospital admission to randomization, SARS -COV -2-RNA/viral load PCR test 
result (negative/positive ), COVI D
-19 abnormal chest x-ray at baseline consistent with COVID -
19 (No/Yes), requiring oxygen at randomization (No/Yes) ,  
.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented. For selected parameters, 
25th and 75th percentiles will also be presented .
Protocol -solicited medical history  will be summarized by  treatment group.
12.3 Treatments
The Safet y set will be used for the analy ses below. Categorical data will be summarized as 
frequencies and percentages. For continuous data, mean, standard deviation, median, 25th and 
75th percentiles, minimum, and maximum will be present ed.
The duration of exposure indaystohydroxychloroquine , azithromy cin, and placebo will be 
summarized by  means of descriptive statistics using the safet y set.
Concomitant medications and significant non-drug therapies prior to and after the start of the
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem and prefe rred term , by treatment group .

Novartis Confidential Page 53of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
12.4 Analysis of the primary  endpoint(s)/estimand(s)
The primary  analysis for this study  will be conducted on the FAS using a treatment policy 
strategy .
12.4.1 Definition of primary  estimand(s)
The primary  objective of the study  is to demonstrate in participants receiving best standard of 
care that the percentage who achieve clinical response with hydroxy chloroquine or 
hydroxychloroquine plus azithromy cinis superior to placebo byDay 15.
The primary efficacy  estimand defined in Section 2.1incorporates as its endpoint clinical 
response byDay 15 defined for p articipants with a pre-morbid oxygen requirement as: 
Discharge (or ready to discharge as evidenced by normal body  temperature and respiratory  rate, 
and stable oxygen saturation on ambient air or ≤2L supplemental oxygen) OR survival without 
need for m echanical ventilation. The clinical response endpoint for participants without a pre -
morbid oxygen requirement is defined as: discharge (or ready for discharge) OR survival 
without need for mechanical ventilation or ox ygen supplementation for the last 24 hours.
The components of clinical response will be derived from the disease status CRF that will be 
collected whenever there is a change in disease status (Section 8.3.1). Day 15 is the last study  
day where these criteria can be met. Study  participants can meet the clinical response criteria 
prior to Day 15if the criteria for discharge are met. Handling of missing data are provided in 
Section 12.4.4 .
12.4.2 Statistical model, hypothesis, and method of analy sis
The number sand percentages of responders will be summarized by treatment group . The 
difference in observed response rates between active treatment groups and placebo arms will 
be presented along with 95% confidence intervals. Thestatistical hy pothesis tested for clinical 
response is that there is no difference in the proportion of participants achieving clinical 
response at Day 15 with hydroxychoroquine or hydroxychloroquine plus azithromy cin plus 
versus placebo. 
Let pjdenote the proportion of clinical responders at Day 15for treatment groups j, j = 0,1,2 
where
0 corresponds to placebo 
1 corresponds to h ydrox ychloroquine plus azithromy cin 
2 corresponds to h ydrox ychloroquine 
The following statistical hy potheses will be tested to address the primary  efficacy  objective:
H1:   (    )
  (    )= 1, HA1:   (    )
  (    )≠1
H2:   (    )
  (    )= 1, HA2:   (    )
  (    )≠1
In other words, 
H1: hydroxychloroquine plus azithromy cin is not different to placebo with respect to the 
likelihood of clinical response byDay 15
Novartis Confidential Page 54of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
H2: hydroxychloroquine is not different to placebo with respect to the likelihood of clinical 
response byDay 15
The primary  efficacy  endpoint of clinica l response at Day 15 in the FAS will be evaluated using 
a logistic regression model with treatment group and whether or not supplemental oxygen is 
required at randomization as explanatory  variables. Odds ratios will be computed for each of 
active treatment comparisons to placebo.  Based on what data is available from the evolving 
COVID -19 literature, it is anticipated that hydroxy chloroquine plus azithromy cin will have a 
greater clinical response than hy droxy chloroquine and thus each of the primary  and seco ndary 
hypothes es will be tested first in a closed testing procedure in order to preserve family wise Type 
I error rate at0.05 two -sided.   Details of the closed testing procedure are provided in Section
12.5.
12.4.3 Handling of remaining intercurrent events of primary  estimand
The primary  analysis has incorporated all potential intercurrent events related to treatment or 
concomitant therapy  as part of the treatment of interest attribute of the estimand and no other 
intercurrent events are necessary .
12.4.4 Handling of missing values not related to intercurrent event
Given that the participants in this clinical trial will be hospitalized for their participation ,it is 
not expected that there will be any  additional miss ing data in the primary  analy sis.
12.4.5 Sensitivity analy ses for primary  endpoint/estimand
The following sensitivity analy ses will be performed for the primary  estimand, to assess the 
robustness of the estimation in the presence of deviations from the assumptions specified in the 
primary  anal ysis.
In order to determine the robustness of the logistic regression model used for the 
primary  anal ysis of clinical response at Day  15, a non -parametric regression model 
(Koch et al 1998 ) will also be evaluated using the same explanatory  variables as the 
logistic regression model.
12.4.6 Supplementary  analysis
No supplementary  anal ysis are planned at this time .
12.4.7 Supportive analy ses
The primary  efficacy  endpoint will be evaluated with respect to the following subgroups
Age (18 -65, > 65 y ears)
SpO2 ( ≤94% > 94%)
Requiring supplemental oxygen at the time of randomization (No/Yes)
The primary  estimand will be applied here to each of these subgroups variables adding the 
subgroup variable and treatment group by subgroup interaction to the model to evaluate whether 
there is an y association between the level of subgroup variable and treatment.
Novartis Confidential Page 55of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
12.5 Analysis of secondary  estimands
Viral clearance at Day 15
The secondary efficacy  endpoint of the percentage of participants with negative or below LLOQ 
-SARS -COV -2 based on PCR by Day 15 will determined based on the PCR test that is 
performed at Day 6, Day 10, and Day 15/Day  of discharge . Data available in the literature would 
indicate that when viral clearance is achieved ,that participant swill not reverse their viral 
clearance during the 15 -day period.  The endpoint will be evaluated in the FAS using a logistic 
regression model with treatment group and whether or not supplemental oxygen is required at 
randomization as explanatory  variables. Odds ratios will be computed for each of active 
treatment comparisons to placebo.  Based on what data is available from the evolving COVID -
19 literature, it is anticipated that hydroxychloroquine plus azithromy cinwill have a greater 
viral response than hydroxy chloroquine and thus will be tested first for the secondary  endpoints 
in the closed testing procedure to preserve famil ywise Type I error rate at 0.05 two -sided.
The hy potheses in the closed testing procedur e will be evaluated in the following order:
H1: hydroxychloroquine plus azithromy cin is not different to placebo with respect to the 
percentage of participants achieving clinical response byDay 15
H2: hydroxychloroquine is not different to placebo with respect to percentage of participants 
achieving clinical response byDay 15
H3: hydroxychloroquine plus azithromy cin is not different to placebo with respect to the 
percentage of participants achieving viral clearance by Day 15
H4: hydroxychloroquine is not different to placebo with respect to the percentage of 
participants achieving viral clearance by Day 15
Time to SA RS-CoV-2 negativity/ Time to return to pre- morbid oxygen 
requirement /Time to discharge (or ready  for d ischarge)
The event rates for these different endpoints will be estimated with Kaplan -Meier product -limit 
formula.  Greenwood’s formula will be used to estimate the variance of failure rates and to 
derive 95% Z-test based confidence intervals for the difference in event rates between active 
treatment groups and placebo.
12.5.1 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
treatment group .
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate summary  for death including on treatment and post 
treatment deaths will be provi ded. In particular, summary  tables for adverse events (AEs) will 
summarize only on-treatment events, with a start date during the on-treatment period 
(treatment -emergent AEs).
Novartis Confidential Page 56of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
The on -treatment period lasts from the date of first administration of study  treatment to 30days 
after the date of the last actual administration of any  study  treatment.
Adverse events
A treatment -emergent AE is defined as any AE that develops after initiation of the study  
treatments or any event alread y pres ent that worsens following ex posure to the study  treatment. 
All information obtained on adverse events will be display ed by treatment group and participant.
The number (and percentage) of participants with treatment -emergent adverse events (events 
started after the first dose of study  medication or events present prior to start of double -blind 
treatment but increased in severit y based on preferred term) will be summarized in the following 
ways:
by treatment, primary  system organ class and preferred term.
by treatment, primary  system organ class, preferred term and maximum severity .
by treatment, Standardized MedDRA Query  (SMQ) and preferred term.
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events, other significant adverse events leading to discontinuation. 
A participant with multiple adverse events within a primary s ystem organ class is only  counted 
once towards the total of the primary  system organ class.
Vital signs
All vital signs data will be listed by treatment group , participant, and visit/time and if ranges 
are available, abnormalities will be flagged. Summary  statistics will be provided by treatment 
group and visit/time.
ECG
The overall interpretation of the ECGs will be summarized by  treatment group and visit/time.
Any clinically  significant changes in ECG parameters will be summarized by  treatment group .
Summary  statistics will be presented by treatment and visit/time , as appropriate .
Clinical laboratory  evaluations
All laboratory  data will be listed by treatment group , participant, and visit/time and if normal 
ranges are available abnormalities will be flagged. Summary  statistics will be provided by 
treatment and visit/time. Shift tables using the low/normal/high/ (low and high) classification 
will be us ed to compare baseline to the worst on -treatment value.
12.5.2 Biomarkers
All biomarker data will be listed by treatment group, participant and visit. Summary  statistics 
and graphical summaries (including spaghetti plots, boxplots and mean plots with SD) will be 
provided by treatment and visit. The number of values outside of the limits of quantification 
will be reported in each table. Values above the ULOQ will be imputed as ULOQ in graphical 
Novartis Confidential Page 57of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
summaries (with a special symbol) and for the calculation of the summar y statistics. Values 
below the LLOQ will be imputed as LLOQ/2 for these anal yses.
 
 
 
12.7 Interim analy ses
No formal interim analysis is planned for this trial. The primary  endpoint analy sis will be 
performed after all participants have completed Day 15 or discontinued prior to Day 15. A final 
analysis will be performed after all participants have completed their last follow -up visit at Day 
40 (or discontinued prior to Day  40).
12.8 Sample size calculation
12.8.1 Primary  endpoint(s)
Assuming a true treatment difference in clinical r esponse of 20% for hy droxy chloroquine plus
azithromy cin plus SoC vs. placebo plus SoC, and an odds- ratio of at least 2.25, a sample size 
of 148 participants per treatment group (444 overall) provides at least 93% power that the 
primary  analysis will be statistically  significant at the two-sided 5% significance level.  This 
holds for a variety  of different assumptions with respect to treatment and clinical response rates.
These sample size assumptions were evaluated using East Version 6.4.
The sensitivity  of different assumptions for clinical response rate for treatment and control 
groups and effect size on power are summarized in Table 12
-1.
Table 12-1 Sensitivity  of sample size to different response rates for 148 
participants per group (N=444) and treatment differences for level of 
significance alpha = 0.05
HCQ/HCQ plus AZ 
Response Rate (%)Standard of care 
response rate Odds Ratio Treatment
difference (%) Power (%)
50 35 1.86 15 74

Novartis Confidential Page 58of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
HCQ/HCQ plus AZ 
Response Rate (%)Standard of care 
response rate Odds Ratio Treatment
difference (%) Power (%)
50 30 2.33 20 94
50 25 3.00 25 99
60 45 1.83 15 73
60 40 2.25 20 93
60 35 2.79 25 99
70 55 1.91 15 76
70 50 2.33 20 94
70 45 2.85 25 99
12.8.2 Secondary  endpoint(s)
Data available from recent studies published by Gautret (2020) would indicate that viral 
clearance for hydroxychloroquine plus azithromycin i s high. In one study  all participants 
receiving this combination therap y achieved viral clearance by Day 6. Participants receiving 
standard of care generally do not achieve a response rate higher than 50%. However, many of 
these studies are small and often not randomi zed. If one were to assume that 
hydroxychloroquine plus azithromy cin has an 80% response rate by Day 15 and standard of 
care has a 50% response rate by Day 15, under this scenario, using the sample size justified for 
the primary  efficacy  endpoint, the 30% treatment difference corresponds to an odds- ratio of 4.0 
and given 148 participants per treatment group.   There will be more than 99% power to detect 
such a treatment difference.
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Re view Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
informed consent form, consent form updates, participant recruitment procedures (e.g., 
advertisements) and an y other written information to be provided to participants. Prior to stud y 
start, the investigator is required to sign a protocol signature page confirming his/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevan t data and records 
toNovartis /Sponsor monitors, auditors, Novartis /Sponsor Quality  Assurance representatives, 
designated agents of Novartis /Sponsor , IRBs/IECs, and regulatory authorities as required. If an 
Novartis Confidential Page 59of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
inspection of the clinical site is requested by aregulatory  authorit y, the investigator must inform 
Novartis /Sponsor immediately  that this request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last participant last visit) 
and finalization of the study report the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the Novartis clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.).
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novarti s publication policy  training materials provided to you at the trial investigator meetings.
13.4 Qualit y Control and Quality  Assurance
Novartis maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes.
14 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safet y of participants should be 
administered as deemed necessary  on a case by case basis. Under no circumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novart is and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by 
Novarti sand approved by the IRB/IEC and Health Authorities, where required, it cannot be 
implemented.
Novartis Confidential Page 60of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
14.1 Protocol amendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis /Sponsor , health authorities where required, and the IRB/ IEC 
prior to implementation.
Only  amendments that are required for participant safety  may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take an y immediate action required for the safet y of any participant included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be inform ed according to 
local regulations.
Novartis Confidential Page 61of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
15 References
References are available upon request
Amsden G (2005). Anti -inflammatory  effects of macrolides- an underappre ciated benefit in 
the treatment of community -acquired respiratory  tract infections and chronic inflamm atory  
pulmonary  conditions. Journal of antimicrobial chemotherapy 55:10 -21.
Banjanac M, Kos VM, Nujic K, et al (2012). Anti- inflammatory  mechanism of action of 
azithromy cin in L PS-stimulated J774A.1 cells. Pharmacological Research. 66:357-362.
Bosner M, Ke lneric Z, Munic V, et al (2005). Cellular uptake and efflux of azithromy cin, 
erythromy cin, clarithromy cin, telithrom ycin and cethromycin. Antimicrobial agents and 
chemotherap y. 49(6):2372 -2377.
CDER (2013) US Department of Health and Human Services, Food a nd Drug Administration, 
Guidance for Industry : Electronic source data in clinical investigations. Rockville, MD.
Chen, Z et al (2020). Efficacy  of hydroxychloroquine in patients with COVID -19: results of a 
randomized clinical trial. doi: https://doi.org/10.1101/2020.03.22.20040758nce 
Code of federal regulations, Title 21 part 312: I nvestigational new drug application
Colson P, Rolain J, L agier C, et al (2020). Chloroquine and hy droxychloroquine as available 
weapons to fight COVID -19. Int J Antimicrob Agents. Article number:105932.
Dyall J, Coleman C, Hart B, et al (2014). Repurposing of Clinically  developed drugs for 
treatment of middle east respiratory  syndrome coronavirus infection. Antimicrobial agents 
and chemotherap y. 58 (8):4885 -93.
Ferguson NM, Lay don D, Nedjati -Gilani G, et al (2020). I mpact of non -pharmaceutical 
interventions (NPIs) to reduce COVID19 mortality and healthcare demand. 16 March 2020 
Imperial College COVID -19 Response Team.
Furst D, Lindsley  H, Baethge B, et al (1999). Dose -loading with hy droxy chloroquine 
improves the rate of response in earl y, active rheumatoid arthritis. Arthritis and Rheumatism. 
42(2):357-65
Gao J, Tian Z, Yang X (2020). Breakthrough: Chloroquine phosphate has shown apparent 
efficacy  in treatment of COVID -19 associated pneumonia in clinical studies. Bioscience 
trends. 14(1):72-73.
Gautret P, Lagier JC, Parola Philippe, et al (2020). Hy droxy chloroquine and azithromy cin as a 
treatment of COVID -19: results of an open- label non -randomized clinical trial. Int J 
Antimicrob Agents. 105949.
Koch G, Tangen C, Jung J, et al (1998). Issues for covariance anal ysis of dichotomous and 
ordered categorical data from randomized clinical trials and non -parametric strategies for 
addressing them. Statistics i n medicine. 17:1863 -92.
Liu, Jia, Ruiy uan Cao, Mingy ue Xu, et al (2020). Hydroxy chloroquine, a less toxic derivative 
of chloroquine, is effective in inhibiting SARS -CoV -2 infection in vitro. Cell Discovery  
volume 6, Article number: 16.
Novartis Confidential Page 62of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Lover AA (2020). Qua ntify ing treatment effects of hy droxychloroquine and azithromy cin for 
COVID -19: A secondary anal ysis of an open label, non- randomized clinical trial. 
https://doi.org/10.1101/2020.03.22.20040949doi: medRxiv preprint.
Mattila MJ1, Vanakoski J, I dänpään -Heikk ilä JJ. (1994) Azithromy cin does not alter the 
effects of oral midazolam on human performance. Eur J Clin Pharmacol. 47(1):49-52.
Mehta P, McAuley  D, Brown M, et al (2020). COVD19: consider cy tokine storm sy ndromes 
and immunosuppression. The Lancet. 395(10 229):1033 -1034.
Ponticelli C and Moroni G (2017). Hy droxychloroquine in sy stemic lupus ery thematosus 
(SLE). Expert opinion on drug safet y. 16(3):411 -9.
Schrezenmeier E, Dorner T (2020). Mechanisms of action of h ydrox ychloroquine and 
chloroquine: implicatio ns for rheumatology . Nature rev Rheumatol. 16:155-166.
Tett S, Cutler D, Day  R et al (1988). A dose -ranging stud y of the pharmacokinetics of 
hydroxychloroquine following intravenous administration to healthy  volunteers. Br J Clin 
Pharmac. 26:303 -13.
Tett S, Cutler D, Day  R et al (1989). Bioavailability  of hy droxy chloroquine tablets in healthy  
volunteers. Br J Clin Pharmac. 27:771-79.
van den Borne BE, Dijkmans BA, de Rooij HH, et al (1997). Chloroquine and 
hydroxychloroquine equally  affect tumor necro sis factor -alpha, interleukin 6, and interferon -
gamma production b y peripheral blood mononuclear cells. J Rheumatol. Jan;24(1):55 -60.
Vincent MJ, Bergeron E, Benjannet S, et al (2005). Chloroquine is a potent inhibitor of SARS 
coronavirus infection and spr ead. Virol J. 2:69.
Wei Y, Ny gard GA, Ellertson SL , Khalil SK. (1995) Stereoselective disposition of 
hydroxychloroquine and its metabolite in rats. Chirality  7:598 –604.
WHO (2020). https://www.who.int/docs/default- source/coronaviruse/situation-
reports/20200401- sitrep-72- covid- 19.pdf?sfvrsn=3dd8971b_2
Yao X, Ye F, Zhang M et al (2020). In vitro antiviral activity  and projection of optimized 
dosing design of h ydrox ychloroquine for the treatment of Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS -CoV -2). Clinical I nfectious diseases. Ciaa 237.
Yeates RA1, Laufen H, Zimmermann T (1996). Interaction between midazolam and 
clarithrom ycin: comparison with azithromy cin. Int J Clin Pharmacol Ther. 34(9):400 -5.
Novartis Confidential Page 63of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
Investigators are responsible for reviewing abnormal laboratory  values forclinical significance, 
signing the laboratory  reports to indicate their review, and reporting values considered clinically 
significant in the appropriate eCRF.
Any clinically  significant abnormal laboratory  value should be evaluated and followed -up by
the investigator until normal or a cause for the abnormality  is determined.
See Append ix 2for specific liver event and laboratory  test trigger definitions and follow -up
requirements.
See Append ix 3for specific renal alert criteria and actions.
Post-baseline vital signs will be flagged as notable abnormalities as follows:
1. Sy stolic/Diastolic blood pressure: ≥25% decrease or ≥25% increase from baseline
2. Pulse: ≥110 bpm with ≥15% change from baseline, or <50 bpm with ≥15% change from 
baseline
Novartis Confidential Page 64of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
16.2 Appendix 2: Suggested Liver event and laboratory  trigger 
definition s & follow -up requirements
Table 16-1 Liver event and laboratory  trigger definitions
Definition/ threshold
Liver laboratory triggers
If ALT, AST and total bilirubin normal at 
baseline: ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known 
bone pathology)
Total bilirubin > 3 × ULN (in the absence of 
known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or 
AST > 3 × ULN and Total bilirubin > 2 × ULN 
[mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent 
term)
ALT or AST > 3 × ULN accompanied by 
(general) malaise, fatig ue, abdominal pain, 
nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a 
liver toxicity*
If ALT or AST abnormal at baseline: ALT or AST > 2x baseline or > 300 U/L 
(whichever occurs first)
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms 
ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, AST: Aspartate aminotransfer ase, 
ULN: upper limit of normal
Table 16-2 Follo w up requirements for liver laboratory  trigge rs with liver 
symptoms
ALT TBL Liver Symptoms Action
ALT increase without bilirubin increase:
If normal at 
baseline:
ALT > 3 x ULNNormal
For participants 
with Gilbert’s 
syndrome: No 
change in 
baseline TBLNoneNo change to 
study treatment
Measure ALT, 
AST, ALP, GGT, 
TBIL, INR, 
albumin, CK, and 
GLDH in 48 -72 
hours.
Follow -up for 
symptoms.If elevated at 
baseline:
ALT > 2 x baseline
or > 300 U/L 
(whichever occurs 
ﬁrst)
If normal at 
baseline:
ALT > 5 x ULN for 
more than two 
weeksNormal
For participants 
with Gilbert’s 
syndrome: No NoneInterrupt study 
drug
Measure ALT, 
AST, ALP, GGT, 
TBIL, INR, 
Novartis Confidential Page 65of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
ALT TBL Liver Symptoms Action
If elevated at 
baseline:
ALT > 3 x baseline
and >10 x ULNchange in 
baseline TBLalbumin, CK, and 
GLDH in 48 -72 
hours.
Follow -up for 
symptoms.
Initiate close 
monitoring and 
workup for 
competing 
etiologies.
Study drug can 
be restarted only 
if another 
etiology is 
identi ﬁed and 
liver enzy mes 
return to 
baseline.If normal at 
baseline:
ALT > 8 x ULNNormal
None
ALT increase with bilirubin increase:
If normal at 
baseline:
ALT > 3 x ULNTBL > 2 x ULN 
For participants 
with Gilbert’s 
syndrome: 
Doubling of 
direct bilirubinNoneIf elevated at 
baseline:
ALT > 2 x baseline
If normal at 
baseline:
ALT > 3 x ULN Normal or 
elevatedSevere fatigue, 
nausea, vomiting, 
right upper 
quadrant painIf elevated at 
baseline:
ALT > 2 x baseline
Table 16-3 Follo w up requirements for liv er laboratory  triggers
Criteria Actions required Follow -up monitoring
Total Biliru bin (isolated)
>1.5 –3.0ULN Maintain treatment
Repeat LFTs within 48 -72 
hoursMonitor LFTs weekly until 
resolutionato ≤ Grade 1 or to 
baseline
> 3 -10 × ULN (in the absence 
of known Gilbert s yndrom e)Interrupt treatment
Repeat LFT within 48 -72 
hours
Establish causality
Record the AE and 
contributing factors (e.g. 
conmeds, med hx, lab) in 
the appropriate CRFMonitor LFTs weekly until 
resolutionato ≤ Grade 1 or to 
baseline (ALT, AST, total 
bilirubin, Alb, PT/INR, ALP and 
GGT)
Test for hemoly sis (e.g. 
reticulocytes, haptoglobin,
unconjugated [indirect] 
bilirubin)
> 10 x ULN Discontinue the st udy 
treatment immediately
Establish causality
Record the AE and 
contributing factors(e.g. 
conmeds, med hx, lab)in 
the appropriate CRFALT, AST, total bilirubin, Alb, 
PT/INR, ALP and GGT unti l 
resolutiona(frequency at 
investigator discretion)
Novartis Confidential Page 66of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
Criteria Actions required Follow -up monitoring
General symptoms
Any AE potentially indicative of 
a liver toxicity*Consider study treatment 
interruption or 
discontinuation
Establish causality
Record the AE and 
contributing factors(e.g., 
conmeds, med hx, lab)in 
the appropriate CRFInvestigator discretion
aResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation, and (5) death.
*(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serology  tests, imaging and pathology  assessments, hepatologist’s consultancy ; 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  of 
concomitant drug use, exclusion of underl ying liver disease.
Novartis Confidential Page 67of 67
Clinical Trial Protocol (Version No. 00) Protocol No. CJW T629A12301
16.3 Appendix 3: Suggested Specific Renal A lert Criteria and Actions 
and Event Follow -up
Table 16-4 Specific Renal A lert Criteria and A ctions
Serum Event
Serum creatinine increase 25 -49% compared 
to baselineConfirm 25% increase after 24- 48h
Follow up within 2 -5 days
Acute kidney injury: serum creatinine increase 
≥50% compared to baselineFollow up within 24 - 48h if possible
Evaluate the need for study treatment 
interruption or discontinuation
Consider specialized treatment
Urine Event
New dipstick proteinuria ≥1+
Albumin -or Protein -creatinine ratio increase ≥2-
fold
Albumin -creatinine ratio (ACR) ≥30 mg/g or
≥3 mg/mmol;
Protein -creatinine ratio (PCR) ≥150 mg/g or
≥15 mg/mmolConfirm value after 24- 48h
Perform urine microscopy
Evaluate the need for study  treatment interruption 
/ or
discontinuation
New dipstick glycosuria ≥1+ not due to diabetesBlood glucose (fasting)
Perform serum creatinine, ACR
New dipstick hematuria ≥1+ not due to traumaUrine sediment microscopy
Perform serum creatinine, ACR
For all renal events:
Document contributing factors in the CRF: co -medication, other co -morbid conditions, and additional
diagnostic procedures performed
Monitor subject regularly (frequency at investigator’s discretion) until either:
Event resolution: sCr within 10% of baseline or protein -creatinine ratio within 50% of baseline, or
Event stabilization: sCr level with ± 10% variability over last 6 months or protein -creatinine ratio
stabilization at a new level with ± 50% variability over last 6 months.